

YEDİTEPE UNIVERSITY

FACULTY of MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2014 – 2015

Student's :

Name:.....

Number:.....

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

CONTENTS	Page
AIMS AND OUTCOMES OF MEDICAL EDUCATION PROGRAM.....	1
PHASE III COORDINATION COMMITTEE.....	5
DESCRIPTION OF THE PHASE	6
PHASE CONTENT	6
EXECUTIVES OF ACADEMIC YEAR	6
AIMS AND OBJECTIVES OF PHASE III.....	7
ACADEMIC CALENDAR 2014 - 2015.....	10
STUDENT COUNSELING.....	12
LIST OF STUDENT COUNSELING.....	13
ASSESSMENTS OF PHASE III.....	15
SCIENTIFIC PROJECTS.....	18
COMMITTEE I INFECTIOUS DISEASES.....	19
COMMITTEE II CARDIOLOGY AND RESPIRATORY SYSTEM.....	29
COMMITTEE III HEMATOPOIETIC SYSTEM.....	42
COMMITTEE IV GASTROINTESTINAL SYSTEM.....	50
COMMITTEE V ENDOCRINE SYSTEM & REPRODUCTIVE SYSTEM.....	59
COMMITTEE VI URINARY SYSTEM	68
COMMITTEE VII NERVOUS SYSTEM & PSYCHIATRY.....	77
COMMITTEE VIII MUSCULOSKELETAL SYSTEM.....	88
CONTACT INFORMATION.....	97

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE
AIM AND OUTCOMES OF MEDICAL EDUCATION PROGRAM,****

*“Consensus Commission Report” based on draft compiled at “*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*”

**© 2011, Yeditepe University Faculty of Medicine

AIMS

The aim of medical education program *is to graduate physicians* who

- ***are aware of*** the local and global health issues
- ***have acquired competence*** in knowledge, skills and attitudes to manage and provide primary health care service
- ***know, apply*** and ***care*** for ethical principles of the medical profession
- ***keep up with*** current knowledge at national and international level
- ***are capable of*** systematical thinking
- ***are*** investigative and questioning
- continually ***renovate*** and ***improve*** themselves
- ***are capable of*** teamwork
- ***use*** technology competently in medicine and related areas
- ***have*** effective communication skills
- ***have*** community leadership qualifications

OUTCOMES

Graduate should be able to:

1) *practice* as a physician,

- oriented towards
 - individual and non-individual factors affecting health
 - sustainment and improvement of healthy condition
 - clinical conditions which
 - are frequent in communityand/or
 - pose high risk for individual or community healthand/or
 - life-threatening or constitute an emergency
- at a competency level appropriate to deliver primary health care services compatible with surrounding context of health determinants.
 - 1.1. **explain** normal structural components of human body, their functions and operational mechanisms at organismal, multisystem, system, organ, tissue, cellular and molecular levels.
 - 1.2. **explain** healthy condition and factors affecting health.
 - 1.3. **explain** and **relates** causes of clinical conditions, courses of effect and outcomes.
 - 1.4. **explain** changes (*i.e. physiological and pathological*) in structural components of body, their functions and operational mechanisms under healthy and clinical conditions.
 - 1.5. **explain** most frequently occurring or most important clinical complaints (*i.e. chief complaint*), symptoms, signs, laboratory and imaging findings and their emergence mechanisms in clinical conditions.
 - 1.6. **explain** current medical and surgical methods used in interventions directed towards health conditions.
 - 1.7. **use** contextually appropriate medical history taking method, out of different types (*e.g. comprehensive, focused or hypothetico-deductive*) and systematically, to gather medical information from healthy individual, patient or patient's companions (*i.e. heteroanamnesis*), in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
 - 1.8. **employ** physical examination methods for systems in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
 - 1.9. accurately **interpret** findings in medical history and physical examination, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
 - 1.10. **implement** diagnostic procedures (*e.g. point of care testing, physician office testing*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
 - 1.11. **select (utilize)** tests shown to be highly effective in clinical decision making by evidence-based medicine from the aspects of reliability, practicality and outcome measures, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition, and **interpret** results.
 - 1.12. **make** clinical decisions (*e.g. benefit estimation, risk estimation, prevention, screening, test requisition, diagnosis, triage, staging, consultation, prognosis, watchful-waiting, intervention, monitoring, end of intervention, discharge, control, end of follow-up*) shown to be highly effective from the aspects of outcome measures by evidence-based medicine, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
 - 1.13. accurately **perform** interventional procedures (*i.e. interventional clinical skills, competencies and proficiencies*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a clinical condition.
 - 1.14. **coordinate** referral or transport of patient, when necessary and with patient-centered approach, to secondary health care institution, without posing any risk to patient's health, security and confidentiality, in case of an encounter with a patient who seeks health care service for a clinical condition.

- 1.15. **manage** request or symptom, healthy or clinical condition, and healthy individual or patient, with beneficiary-centered approach, and with clinical decisions made by analytical and critical thinking, clinical reasoning and problem solving methods, in case of an encounter with a patient who seeks health care service for a health condition.
- 1.16. **execute** protective and therapeutic medical practices that are individual, family and community-oriented, easily accessible, integrated and coordinated, continuous, comprehensive, and based on the principles of confidentiality, in primary health care services.
- 1.17. **identify** factors that pose a high risk to individual and community health, and **determine** individuals or populations at risk in advance or at an early stage and implement the necessary measures.
- 1.18. **value** preventive health services, **offer** primary prevention (*i.e. prevention of diseases for the protection of health*), secondary prevention (*i.e. early diagnosis and treatment*) and tertiary prevention (*i.e. rehabilitation*) services, and **provide** consultancy on these issues.
- 1.19. **provide** life-style consultancy and design services to sustain and improve individual and community health.

2) manage primary health care services.

- 2.1. **manage** health care team in primary health care organization.
- 2.2. **lead** community with sense of responsibility, good behavior and manners in consideration of individual behaviors and social dynamics of community, and if there is a necessity, **develop** projects directed towards health care services.
- 2.3. **define** health management and economics principles, models for organization and finance of health care services.
- 2.4. **use** health care resources with cost-effective manners.

3) advocate individual and community health under all circumstances.

- 3.1. **provide** consultancy services to sustain and promote the health of individual and community.
- 3.2. **explain** epidemiology of clinical conditions, and **define** measures to reduce frequencies.
- 3.3. **describe** completely all high risk factors for the community health (*e.g. natural disasters, nuclear accidents, fire, war, bio-terrorism, etc.*), and **implement** necessary measures in order to prevent effects on health.
- 3.4. **explain** health determinants completely (*e.g. physical environment, social environment, genetic background, individual response -behavior, biology-, health care services, welfare, etc.*), including conditions that prevent access to health care.

4) perform medical practices according to regulatory and ethical principles and in consideration of behavioral sciences, social sciences, and humanities.

- 4.1. **recognize** determinants affecting individual behaviors and attitudes, and social dynamics.
- 4.2. **recognize** basic ethical principles completely, and **distinguish** ethical and legal problems.
- 4.3. **recognize** regulations concerning national and international health systems.
- 4.4. **employ** safety, security and confidentiality principles completely for beneficiaries of health care services, companions and visitors, and health care workers.
- 4.5. **use** medical record and information systems according to regulations and ethical principles.
- 4.6. **value** informed consent taking in the framework of patients' rights, and **employ** fully.
- 4.7. **interpret** historical, anthropological and philosophical evolution of medicine, health and disease concepts, and **relate** to current medical practice.

5) establish correct and effective communication with all stakeholders of health care services and collaborate.

- 5.1. **communicate** by using problem solving abilities during all of professional life with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals and organizations.
- 5.2. **collaborate** with related organizations and institutions, with other professionals and health care workers as a team member through using problem solving abilities.
- 5.3. **communicate** with all stakeholders with consideration of socio-cultural differences.

6) promote self medical knowledge and skills in view of the current scientific developments throughout own career.

- 6.1. **adopt** and **implement** the importance of lifelong self-learning.
- 6.2. **recognize** importance of updating knowledge and skills; **search** current advancements and improve own knowledge and skills.
- 6.3. **speak** at least one foreign language at advanced level to follow the international literature and communicate with colleagues.
- 6.4. **recognize** methods to reach current scientific knowledge, and **use** available technology.
- 6.5. **recognize** principles of evidence-based medicine, and **implement** in health care services.
- 6.6. **develop** and **present** research projects.

7) manage own postgraduate career.

- 7.1. **recognize** and **investigate** postgraduate work domains and job opportunities.
- 7.2. **determine** postgraduate work domains, job opportunities and requirements for application, **distinguish** and **plan** requirements for further training and work experience.
- 7.3. **prepare** a resume, and **recognize** job interview methods.
- 7.4. **recognize** health technologies expected to be implemented in near future and emerging work areas.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**COORDINATION COMMITTEE
(TEACHING YEAR 2014 – 2015)**

Gülderen Yanıkkaya Demirel, MD, Assoc.Prof.(Coordinator)

Özlem Tanrıöver, MD, Assoc. Prof. (Co-coordinator)

Ayşegül Kuşkuçcu, MD, Assist.Prof. (Co-coordinator)

Elif Vatanoğlu, MD, Assist.Prof. (Co-coordinator)

Mehtap Kaçar, MD, Assist.Prof. (Co-coordinator)

ICP III COORDINATION COMMITTEE

Özlem Tanrıöver, MD, Assoc.Prof (Coordinator)

Ayşe Arzu Akalın, MD Assist.Prof. (Co-coordinator)

Turhan Özler, MD, Assist. Prof. (Co-coordinator)

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

DESCRIPTION OF THE PHASE

Physiopathological process and pathological process.

PHASE CONTENT

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

EXECUTIVES OF ACADEMIC YEAR

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepatology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophthalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

AIMS and LEARNING OBJECTIVES of PHASE III

AIMS OF PHASE III

In evidence based manner ;

1. **to remind** anatomy, histology and physiology of body systems,
2. **to convey** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
- 3.1. **to convey** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
- 3.2. **to convey** knowledge on epidemiology,
- 3.3. **to convey** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
- 3.4. **to convey** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of primary health care service,
4. **to convey** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. **to convey** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. **to convey** knowledge on biostatistical analysis,
7. **to convey** basic legal and ethical principles that should be followed in practice of medical profession,
8. **to equip with** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES OF PHASE III

At the end of this phase, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of body systems.
- 2.0. **list** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
- 3.0. **explain** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 4.0. at cellular or tissue level,
 - 4.1. **recognize** morphological characteristics,
 - 4.2. **show** basic pathological changes that occur in clinical conditions.
- 5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
 - 5.1. **explain** mechanisms of destruction at molecule, cell, tissue, organ, system, multi-system and organismal level,
 - 5.2. **describe** structural and functional changes caused,
 - 5.3. **list** clinical courses in time.
- 6.0. **explain** mechanisms of emergence for frequently encountered;
 - 6.1. clinical complaints,
 - 6.2. symptoms,
 - 6.3. signs,
 - 6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 7.0. at multi-system level or related to a body system,
 - for healthy conditions in an individual or community with a request, or
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes,
 - acquisition of subjective or objective data, information and knowledge required for clinical decision making,
 - clinical decision making process,
 - clinical decisions and
 - clinical practiceswhich are required for management at primary health care service level.
- 7.1. practice of history taking and physical examination (*cardiovascular-C2, pulmonary-C2, gastrointestinal-C4, gynecological-C5, breast-C5, neonatal, prepubertal/pubertal-C6, neurological/neuropsychiatric-C7, musculoskeletal-C8*)
- 7.2. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain-C4, urological emergencies-C6, neurological emergencies-C7, trauma-C8*)
- 7.3. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4, pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depression-C7, dementia-C7, musculoskeletal dysfunction-C8*)
- 7.4. laboratory and imaging tests/examinations
 - 7.4.1. based on laboratory disciplines/subdisciplines;
 1. medical biochemistry tests:
 - i. (*venous blood collection-C5*)
 - ii. (*thyroid function tests-C5, diabetes tests-C5*)
 2. medical microbiology tests:
 - i. (*urine sample collection-C1, throat swab specimen-C5, sputum sample collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6, wound sample collection-,blood collection for culture-*)

- ii. *(urine strip/dipstick test-C1, urine culture-C1, rapid screening (antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethral-vaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood culture-)*
 - 3. *medical pathology tests:*
 - i. *(C2, C4, C6, C7, C8, Pap smear collection)*
 - ii. *(C2, C4, C6, C7, C8, Pap smear)*
 - 4. *other laboratory tests:*
 - i. *(peripheral/venous blood collection for hematology tests-C3, blood sample collection for therapeutic drug monitoring-C8)*
 - ii. *(pulmonary function tests-C2, hematology tests for anemia-C3, monitorization of drug therapy-C8)*
- 7.4.2. *imaging tests/examinations based on disciplines/subdisciplines:*
 - 5. *radiological examinations: (radiological examinations in gynecology-C5, breast imaging-C5, uroradiology-C6, conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8)*
 - 6. *nuclear medicine examinations: (nuclear medicine tests in infectious diseases-C1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphy-C2, PET in lung cancer-C2, nuclear medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4, radioisotope imaging of thyroid and parathyroid-C5, renal scintigraphy (GFR, ERPF, Renogram)-C6, brain perfusion scintigraphy-C7, brain PET-C7, bone scintigraphy-C8)*
- 7.4.3. *point of care testing*
 - a. *based on laboratory disciplines/subdisciplines;*
 - 1. *medical biochemistry tests: (diabetes tests-C5, cardiac markers-, coagulation tests-, blood gases-).*
 - 2. *medical microbiology tests: (urine strip/dipstick test-C1, rapid screening (antigen/antibody tests-C5)*
 - 3. *other laboratory tests: (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)*
- 7.5. *making preliminary diagnosis or definitive diagnosis decision*
- 7.6. *making non-intervention or intervention decision*
- 7.7. *practicing non-intervention or intervention*
- 7.8. *referral/transport of healthy individual or patient*

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

ACADEMIC CALENDAR 2014 - 2015

COMMITTEE I		
INFECTIOUS DISEASES		(4 WEEKS)
Beginning of Committee	September 08, 2014	Monday
End of Committee	October 01, 2014	Wednesday
Committee Exam	October 02, 2014	Thursday

Coordination Committee Meeting **September 29, 2014** **Monday**
Religious Holiday **October 03-07, 2014** **Friday-Tuesday**

COMMITTEE II		
CARDIOLOGY AND RESPIRATORY SYSTEM		(8 WEEKS)
Beginning of Committee	October 08, 2014	Wednesday
End of Committee	November 21, 2014	Friday
Committee Exam	November 28, 2014	Friday

Republic Day **October 28-29, 2014** **Tuesday-Wednesday**
Commemoration of Atatürk **November 10, 2014** **Monday**

COMMITTEE III		
HEMATOPOIETIC SYSTEM		(3 WEEKS)
Beginning of Committee	December 01, 2014	Monday
End of Committee	December 15, 2014	Monday
Committee Exam	December 19, 2014	Friday

COMMITTEE IV		
GASTROINTESTINAL SYSTEM		(4 WEEKS)
Beginning of Committee	December 22, 2014	Monday
End of Committee	January 09, 2015	Friday
Committee Exam	January 15, 2015	Thursday
OSCE I (Exam)	January 16, 2015	Friday

New Year **January 1, 2015** **Thursday**
Coordination Committee Meeting **January 5, 2015** **Monday**
MIDTERM BREAK **January 19, 2015** **January 30, 2015**
Make-up Exam I **February 09, 2015** **Monday**

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life. The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.

The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

The topics that will be addressed by the consultants are as follows:

- a. Inform students about the university, faculty and surrounding facilities
- b. Inform students about the courses and help them select courses
- c. Inform students about the education and assessment regulations
- d. Follow students attendance to lectures and success
- e. In case of failure, investigate the causes and cooperate with the students to overcome them
- f. Help students in career planning
- g. Contribute to students adapting the habit of lifelong learning
- h. Guide students to counseling services of the university
- i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
- j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
- k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

The expectations from the student are as follows:

- a) Contribute to improvement of satisfaction level in the problem areas
- b) Report the social and economic conditions that require consultant's help
- c) Specify expectations from the education and the department from which this training is taken
- d) Give feedback on the counseling services regarding their satisfaction level

LIST OF STUDENT COUNSELING PHASE III

NECAT İREM	ABDULHAYOĞLU	DR. ÜNAL USLU
ECE MELİS	ADALET	DR. ÜNAL USLU
DUYGU	ADIBELLİ	DR. ÜNAL USLU
GÖZDE	AKAN	DR. DENİZ KIRAÇ
MEHMET	AKAN	DR. DENİZ KIRAÇ
MEHMET	AŞTI	DR. DENİZ KIRAÇ
HASAN BERKE	ATALAY	DR. ÇİĞDEM KASPAR
HASAN BERK	BARIŞCIL	DR. ÇİĞDEM KASPAR
İREM	BAŞARAN	DR. BAYRAM YILMAZ
ELİF	BAYRAKTAR	DR. BAYRAM YILMAZ
GÖKTUĞ	BORA	DR. KAAAN YÜCEL
OZAN	CENGİZ	DR. KAAAN YÜCEL
NUR BÜKE	ÇABUK	DR. GÜLDEN ÇELİK
HARİKA	ÇAĞLAYAN	DR. GÜLDEN ÇELİK
AYLİN	ÇETİNKAYA	DR. AKİF MAHARRAMOV
ECE NUR	ÇINAR	DR. AKİF MAHARRAMOV
FATMA BEGÜM	ÇOPUR	DR. AKİF MAHARRAMOV
GAMZE BİLGE	DALGIN	DR. GÜLDEN ÇELİK
CEREN	DALKIRAN	DR. TURGAY İSBİR
BURAK	DEMİRCİ	DR. TURGAY İSBİR
ZEYNEP	DEMİRCİ	DR. TURGAY İSBİR
ALPER	DÜNKİ	DR. ELİF VATANOĞLU
EZGİ	ERDAĞ	DR. ELİF VATANOĞLU
CİHAD	ERİM	DR. ELİF VATANOĞLU
EZEL	GEDİK	DR. YEŞİM GÜROL
MÜGE	GÜLER	DR. YEŞİM GÜROL
ECE EMİNE	GÜMÜŞKESEN	DR. YEŞİM GÜROL
GİZEM	GÜRBÜZ	DR. YEŞİM GÜROL
MERVE	GÜRKÖK	DR. ÇAĞATAY ACUNER
BERK	GÜRSOY	DR. ÇAĞATAY ACUNER
MERT	GÜRSOY	DR. ÇAĞATAY ACUNER
DİLAN	HAKYERİ	DR. ÇAĞATAY ACUNER
ZEYNEP	HÜSEYİNOĞLU	DR. BURCU ŞEKER
ZEYNEPGÜL	İNKAYA	DR. BURCU ŞEKER
MUSTAFA BEYKAN	İSTANBULLU	DR. ALEV CUMBUL
UĞUR KAAAN	KALEM	DR. ALEV CUMBUL
RANA SELİN	KARAMAN	DR. ALEV CUMBUL
SEVİM PIRIL	KARASU	DR. ALEV CUMBUL
DENİZ	KAVGACI	DR. ALEV CUMBUL
REBECCA	KELLER	DR. ÖZLEM TANRIÖVER
İBRAHİM UMUR	KEPSUTLU	DR. ÖZLEM TANRIÖVER

ARTUN	KIRKER	DR. ÖZLEM TANRIÖVER
DOĞUŞ	KÖKARTTI	DR. HÜLYA AKAN
FATİH	KÖKDERE	DR. HÜLYA AKAN
AHMET ENES	KÜÇÜKARDALI	DR. HÜLYA AKAN
BASEL	EL MASRİ	DR. HÜLYA AKAN
ÖZNUR	MOLLA	DR. İNCİ ÖZDEN
EMİRHAN	NAS	DR. İNCİ ÖZDEN
FATEMEH	MOHAMMADI NASER	DR. İNCİ ÖZDEN
MÜGE	ORAL	DR. JALE ÇOBAN
MUSTAFA FATİH	ÖĞÜNÇLÜ	DR. JALE ÇOBAN
PIRILTI	ÖZCAN	DR. JALE ÇOBAN
MAHMUT ESAT	ÖZCAN	DR. JALE ÇOBAN
ESİN	ÖZÇELEBİ	DR. ARZU AKALIN
PINAR	ÖZEN	DR. ARZU AKALIN
BEYZA	ÖZER	DR. ARZU AKALIN
AYBERK	ÖZKAVAKLI	DR. ARZU AKALIN
BESTE	ÖZTÜRK	DR. ECE GENÇ
NEVA	ÖZTÜRKER	DR. ECE GENÇ
BAHAR	PEZÜKLİ	DR. ECE GENÇ
VIOLA	RIGOTTİ	DR. FERDA KALEAĞASIOĞLU
ONUR	SÖKÜCÜ	DR. FERDA KALEAĞASIOĞLU
CEM	ŞAKAR	DR. AYŞEGÜL KUŞKUCU
UĞUR	ŞEN	DR. AYŞEGÜL KUŞKUCU
ENVER	ŞENBAYRAM	DR. AYŞEGÜL KUŞKUCU
EMİR	ŞENOCAK	DR. AYŞEGÜL KUŞKUCU
RECEP	TEMEL	DR. FERDA ÖZKAN
ORHUN UFUK	TİPİ	DR. FERDA ÖZKAN
AHMET FATİH	USLU	DR. İŞİN DOĞAN EKİCİ
BERFİN GİZEM	USLU	DR. İŞİN DOĞAN EKİCİ
RAGİBE BÜŞRA	USTA	DR. İŞİN DOĞAN EKİCİ
MERİÇ	ÜLGEN	DR. İŞİN DOĞAN EKİCİ
FATMA TUĞÇE	YAVUZ	DR. GÜLDEREN YANIKKAYA DEMİREL
EYLÜL	YERAL	DR. GÜLDEREN YANIKKAYA DEMİREL
ASLI DENİZ	YERLİKAYA	DR. ÇAĞATAY ACUNER
MEHMET İSKENDER	YILDIRIM	DR. GÜLDEREN YANIKKAYA DEMİREL
CEMRE	YILMAZ	DR. GÜLDEREN YANIKKAYA DEMİREL
HAZAL	YILDIZ	DR. SONER DOĞAN
MUSTAFA FADIL	YUNIS	DR. SONER DOĞAN
FATMA PINAR	ZİYADANOĞLU	DR. SONER DOĞAN
BURHAN	ZORLU	DR. SONER DOĞAN

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

ASSESSMENTS

Assessments table will be made with consideration of each learning objective for each committee and will be announced and explained in introductory lectures at the beginning of the committee.

EXAMINATION MATRIX

MD 320 Introduction to Clinical Sciences

Assessment Modalities

- **WE: Written (Theoretical) Exams**
 - MCQ: Multiple Choice Questions.
 - EMQ: Extended Match Questions.
- **PE: Practical Exams**
 - OSCE: Objective Structured Clinical Exam*
- **SP: Scientific Projects** (Assessment will be based on project proposals written by students)

*A form of performance-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat standardized patients who present with some type of medical problem.

Written (Theoretical) Exams (WE)

- **Committee Exams (CE)**
 - Number of Questions: 100
 - Question Types: 10% EMQ**, 90% MCQ
- **Final Exam (FE)**
 - Question Number: 200
 - Question Types: 100% MCQ
- **Incomplete Exam (IC)**
 - Question Number: 100
 - Question Type: 100% MCQ

**Percentage that will be reflected in total points of exam. Does not correspond to the exact number of questions.

Term Score (Pass or Fail) Calculation*:**

- Term Score=(60% of CE Average) + (40% of Final Score or Incomplete Score)
 - Final Score= (OSCE₁ 5%) + (OSCE₂ 5%) + (SP 4%) + (FE 86%)
 - Incomplete Score= (OSCE₁ 5%) + (OSCE₂ 5%)+(SP 4%) + (IC 86%)

*****Fail: FE<50 or Term Score<50 Pass: Term Score>50**

- ***The distribution of questions in the question distribution tables in all exams could be changed by the coordinators.***

What is OSCE?

The objective structured clinical examination (OSCE) is a proven valid and reliable, used both for formative and summative tool for assessing the clinical skills of medical students (1-3).

OSCE is a type of performance-based examination used to measure a student's clinical competence. During an OSCE, students are observed and evaluated in which they interview, examine and write prescriptions to standardized patients who present with a medical problem.

What is the infrastructure of your laboratory?

We have three examination room designed as doctors office which are monitored by 360 degrees cameras, we have an observer room with a one sided mirror and a control room equipped with computers and monitoring stations.

How is the performance evaluated?

Monitored exam rooms are used for taking a history from a standardized patient, performing a physical examination or diagnostic procedure, or teaching/counseling/advising a patient. A rating form or standardized checklist is used for the evaluation criteria.

A student is asked to answer questions, write a report or a prescription, or interpret findings such as lab reports and X-rays. The types of problems portrayed in an OSCE are those students would commonly see in a clinic or hospital. OSCE stations are mostly planned clinical encounters in which a student interacts with a standardized patient (SP). Evaluation criteria are based on course objectives and student learning activities.

References:

1. Harden RM, Gleeson FA. Assessment of clinical competence using an objective structured clinical examination (OSCE). *Med Educ* 1979;13:41–5.
2. Cohen R, Reznick RK, Taylor BR, Provan J, Rothman A. Reliability and validity of the objective structured clinical examination in assessing surgical residents. *Am J Surg.* 1990; 160:302-5.
3. Newble DI. Assessing clinical competence at the undergraduate level. *Med Educ.* 1992; 26:504-11.

Yeditepe University Faculty of Medicine Exam Rules

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
Sign your sheets – Students must sign their multiple-choice answer sheets and/or written-answer sheets.
- **Other activities requiring disciplinary action-** Students must not give or receive assistance of any kind during the exam. Gaining access to exam questions before the exam; • Using an unauthorized calculator or other mechanical aid that is not permitted. • Looking in the exam book before the signal to begin is given. • Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given. • Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired. • Having access to or consulting notes or books during the exam. • Looking at or copying from another student's paper. • Enabling another student to copy from one's paper. • Talking or otherwise communicating with another student during the exam or during the read through period. • Disturbing other students during the exam. • Consulting other persons or resources outside the exam room during the exam. • Copying questions or answers either on paper or with an electronic device to take from the exam room. • Taking an exam book or other exam materials from the exam room. • Taking an exam in place of another student. • Arranging to have another person take an exam for the student. • Threatening or verbally abusing a supervisor or proctor responsible for curbing or reporting improper conduct. • Unprofessional and/or unruly behavior towards any Yeditepe University staff, supervisors, proctors, or volunteers at any time. • Disclosing the contents of an exam to any other person. • Failing to remain in the exam room for a given period of time by the supervisors or proctors. • Failing to follow other exam instructions.
- Students who assist in or are complicit with cheating could also be in violation of the Policy. Thus, students who become aware of their peers either facilitating academic misconduct or committing it should report their suspicions to exam or test observers for investigation.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students: published in the Official Gazette on August 18th, 2012). The standard administrative sanctions include: the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may lose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.

SCIENTIFIC PROJECTS

The aim of Scientific Projects program is to develop awareness in medical students for the importance of scientific projects in profession and provide them opportunity to gain knowledge, skills and attitudes in writing and conducting a scientific project. Throughout the year, each Phase Three student is expected to prepare a scientific project proposal. Students are free to choose their research area and advisor for their prospective research project. Students who wish to apply for a “TUBITAK 2209-A National Grant Program for University Students” has to send in their proposals before February 2015, the rest should hand in their proposals before the end of March. Scientific Projects have four (4) points contribution to final exam results, evaluation scale for projects is as follows:

CRITERIA	EVALUATION POINTS				
	Very Good	Good	Acceptable	Weak	Bad
Is the question/ problem presented clearly?	0.5	0.4	0.3	0.2	0.1
Creativity/originality of the Project	0.5	0.4	0.3	0.2	0.1
Is set up of the Project suitable to obtain aims?	0.5	0.4	0.3	0.2	0.1
Presentation of aims in an easy to understand format	0.5	0.4	0.3	0.2	0.1
Review of project proposal in light of literature	0.5	0.4	0.3	0.2	0.1
Proposal presentation in correct format	0.5	0.4	0.3	0.2	0.1
Does proposal explain the project's significance and contributions well?	0.5	0.4	0.3	0.2	0.1
Project calendar presentation	0.5	0.4	0.3	0.2	0.1
TOTAL POINTS	4.0				

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**INFECTIOUS DISEASES
COMMITTEE I**

DISTRIBUTION of LECTURE HOURS

September 08, 2014 – October 02, 2014

COMMITTEE DURATION: 4 WEEKS

DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	IDCM	16		2 (4 Groups)		18
• PHARMACOLOGY	PC	15				15
• PATHOLOGY	PT	8				8
• PUBLIC HEALTH	PH	8				8
• BIOMEDICAL ETHICS & DEONTOLOGY	BED	8				8
• CLINICAL SKILLS LABORATORY	CSL			3 (4 Groups)		3
• BIostatISTICS	BS	2			2	4
• INTERNAL MEDICINE	IM	2				2
• PATHOPHYSIOLOGY	PP	2				2
• FAMILY MEDICINE	FM	2				2
• MEDICAL GENETICS	MG	2				2
• EMERGENCY MEDICINE	EM	1				1
• PEDIATRICS	PED	1				1
• SCIENTIFIC PROJECTS-III	SP	1				1
TOTAL		68		5	2	75

Coordination Committee

HEAD	Gülden Çelik MD Prof
SECRETARY	Yeşim Gürol, MD Assoc. Prof
MEMBER	Meral Sönmezoğlu, MD Assoc. Prof
MEMBER	Sezgin Sarıkaya, MD Assoc. Prof
MEMBER	Ayşegül Ç. Kuşkuçcu, MD PhD Assist Prof (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**INFECTIOUS DISEASES
LECTURERS**

DISCIPLINE	LECTURERS
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof. Yeşim Gürol, MD Assoc. Prof. İ. Çağatay Acuner, MD Assoc Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof. Ferda Kaleağasıoğlu, MD, Assoc.Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assist. Prof.
PUBLIC HEALTH	Erol Sezer, MD Prof Hale Arık Taşyikan, MD Assist Prof
FAMILY MEDICINE	Güldal İzbirak, MD Assoc.Prof. Özlem Tanrıöver, MD Assoc.Prof.
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD Assist. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**INFECTIOUS DISEASES
COMMITTEE I**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. **to convey** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. **to convey** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. **to convey** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. **to convey** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. **to convey** biostatistical knowledge required in design of medical research,
10. **to convey** basic knowledge on phytotherapy,
11. **to convey** necessary knowledge on genetical basis of clinical conditions,
12. **to equip with** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **explain** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 2.1. **recall** structures, and
- 2.2. **explain** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 3.0. **classify** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,
- 4.0. **explain** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 5.0. **explain** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 6.0. **explain** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 7.0. **explain** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,
- 8.0. **explain** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 9.0. at multi-system level or related to a body system,
 - for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 9.1. practice of history taking and physical examination
- 9.2. evaluation of emergency case (sepsis and septic shock-C1)
- 9.3. approach to healthy individual or patient (fever-C1)
- 9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)
- 9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)
- 9.6. point of care testing (urine strip/dipstick test-C1)
- 9.7. making preliminary diagnosis or definitive diagnosis decision
- 9.8. making non-intervention or intervention decision
- 9.9. practicing non-intervention or intervention
- 9.10. referral/transport of healthy individual or patient
- 10.1. **list** goals and principles of drug use,
- 10.2. **describe** effects,
- 10.3. **explain** mechanism of action (pharmacodynamics),
- 10.4. **list** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug interactions and side effects,
- 10.5. **explain** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antimalarial, antihelminthic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

- 11.0. **explain** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,
- 12.0. **define** approaches (education, sanitation, hygiene, disinfection/antiseptics/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,
- 14.0. **explain** hereditary immune system disorders,
- 15.0. **explain** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
- 16.0. **define** biostatistical knowledge required in design of medical research (research design, planning medical research,
- 17.0. **explain** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),
- 18.0. **perform** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.
- 15.0. **explain** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
- 16.0. **define** biostatistical knowledge required in design of medical research (research design, planning medical research,
- 17.0. **explain** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),
- 18.0. **perform** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE I INFECTIOUS DISEASES						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	Y. Gürol	3	1	0	4
1.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu	10	3	2	15
4.0.,5.0.	PT	F. Özkan	5	1	0	6
4.0.,5.0.	PT	I. D. Ekici	5	1	1	7
4.0.,5.0.,8.0.	PP	M. Kaçar	3	1	1	5
6.0.,7.0.,11.0.,12.0.	PH	R.E. Sezer	5	1	1	7
6.0.,7.0.,11.0.,12.0.	PH	H.A.Taşyikan	5	2	0	7
8.0.,9.0., 9.1.	IM	Y. Küçükardalı	3	1	1	5
9.2.	EM	S. Sarıkaya	1	1	1	3
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	Ö. Tanrıöver	1	1	1	3
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	G. İzbrak	1	1	0	2
9.4.	IDCM	G. Çelik	9	2	1	12
10.0.	PC	E. Genç	6	2	1	9
10.0.	PC	F. Kaleağasıoğlu	14	2	0	16
14.0.	MG	A. Ç. Kuskucu	3	1	1	5
15.0.	BED	E. Vatanoglu	11	3	1	15
16.0.	BS	Ç. Kaspar	5	1	1	7
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu / G. Çelik	2	-	-	2
10.0.	PC	F. Kaleağasıoğlu / E. Genç	2	-	-	2
4.0.,5.0.	PT	I. D. Ekici / F. Özkan	1	-	-	1
TOTAL			5	-	-	5

PHASE III COMMITTEE I INFECTIOUS DISEASES

I. WEEK

DAY	HOUR	SUBJECT	LECTURER
08-Sep-2014	14:00-14:50	Introduction to Phase III	Phase III Coordination Committee
MONDAY	15:00-15:50	Semiology-I	Y. Küçükardalı
	16:00-16:50	Semiology-II	Y. Küçükardalı
	17:00-17.50	Independent study hours	
09-Sep-2014	09.00-09.50	Diagnosis of Infectious Diseases I	G. Çelik
TUESDAY	10.00-10.50	Diagnosis of Infectious Diseases II	G. Çelik
	11.00-11.50	Introduction to Antimicrobial Chemotherapy	F. Kaleağasıoğlu
	12.00-12.50	Introduction to the Course I	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Introduction to the Course II	E. Vatanoğlu
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
10-Sep-2014	09.00-09.50	β Lactam Antibiotics I	F. Kaleağasıoğlu
WEDNESDAY	10.00-10.50	β Lactam Antibiotics II	F. Kaleağasıoğlu
	11.00-11.50	Physician-Patient Relationship I	E. Vatanoğlu
	12.00-12.50	Physician-Patient Relationship II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
11-Sep-2014	09.00-09.50	Public Health and Communicable Diseases-I	R.E. Sezer
THURSDAY	10.00-10.50	Public Health and Communicable Diseases-II	R.E. Sezer
	11.00-11.50	Epidemiology of Communicable Diseases I	H.A.Taşyikan
	12.00-12.50	Epidemiology of Communicable Diseases II	H.A.Taşyikan
	13.00-13.50		
	14.00-14.50	Vancomycin & Other Antimicrobial Drugs	F. Kaleağasıoğlu
	15.00-15.50	Macrolids	F. Kaleağasıoğlu
	16.00-16.50	Scientific Project - III: Project Writing	G. Y. Demirel
	17.00-17.50	Independent study hours	
12-Sep-2014	09.00-09.50	Tissue Response to Infections	I. D. Ekici
FRIDAY	10.00-10.50	Pathology of Mycobacterial Infections	I. D. Ekici
	11.00-11.50	Tuberculosis & Other Mycobacterial Infections I	İ.Ç. Acuner
	12.00-12.50	Tuberculosis & Other Mycobacterial Infections II	M. Sönmezoğlu
	13.00-13.50		
	14.00-17.50	Independent study hours	

II. WEEK			
DAY	HOUR	SUBJECT	LECTURER
15-Sep-2014 MONDAY	09.00-09.50	Pathophysiology of Infectious Diseases I	M. Kaçar
	10.00-10.50	Pathophysiology of Infectious Diseases II	M. Kaçar
	11.00-11.50	Principles of Autonomy and Informed Consent I	E. Vatanoğlu
	12.00-12.50	Principles of Autonomy and Informed Consent II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Prevention and Control of Communicable Diseases I	R.E. Sezer
	15.00-15.50	Prevention and Control of Communicable Diseases II	R.E. Sezer
	16.00-16.50	Investigation of a Disease Outbreak or Epidemic I	H.A.Taşıyan
	17.00-17.50	Investigation of a Disease Outbreak or Epidemic II	H.A.Taşıyan
16-Sep-2014 TUESDAY	09.00-09.50	Pathology of the Parasitic Infections	F. Özkan
	10.00-10.50	Parasitic Infections I	Y. Gürol
	11.00-11.50	Fungal and parasitic skin and soft tissue infections	Y. Gürol
	12.00-12.50	Pathology of Fungal Infections	F. Özkan
	13.00-13.50		
	14.00-14.50	Introduction of Clinical Genetics	A. Ç. Kuşkucu
	15.00-15.50	Inherited Immun System Disorders	A. Ç. Kuşkucu
	16.00-16.50	Confidentiality and Truthfulness I	E. Vatanoğlu
	17.00-17.50	Confidentiality and Truthfulness II	E. Vatanoğlu
17-Sep-2014 WEDNESDAY	09.00-09.50	Pathology of Mycobacterial Infections	F. Özkan
	10.00-10.50	Pathology of Bacterial Infections	F. Özkan
	11.00-11.50	Antimycobacterial Drugs	E. Genç
	12.00-12.50	Quinolones	F. Kaleağasıoğlu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
18-Sep-2014 THURSDAY	09.00-09.50	Bacterial and Viral Skin & Soft Tissue Infections	M. Sönmezoğlu
	10.00-10.50	Zoonotic Diseases I	M. Sönmezoğlu
	11.00-11.50	Zoonotic Diseases II	M. Sönmezoğlu
	12.00-12.50	Parasitic infections II	M. Sönmezoğlu
	13.00-13.50		
	14.00-14.50	Antifungal Drugs	F. Kaleağasıoğlu
	15.00-15.50	Antiprotozoal Drugs	F. Kaleağasıoğlu
	16.00-16.50	Research Design	Ç. Kaspar
	17.00-17.50	Research Design	Ç. Kaspar
19-Sep-2014 FRIDAY	09.00-09.50	Antimalarial Drugs	F. Kaleağasıoğlu
	10.00-10.50	Antiviral Drugs	F. Kaleağasıoğlu
	11.00-11.50	Hospital Infection	M. Sönmezoğlu
	12.00-12.50	Febrile Neutropenia	M. Sönmezoğlu
	13.00-13.50		
	14.00-17.50	Independent study hours	

III. WEEK

DAY	HOUR	SUBJECT	LECTURER
22-Sep-2014 MONDAY	09.00-09.50	Aminoglycosides	E. Genç
	10.00-10.50	Sulfonamides, Chloramphenicol & Tetracyclines	E. Genç
	11.00-11.50	Pathology of Viral Infections I	I. D. Ekici
	12.00-12.50	Pathology of Viral Infections II	I. D. Ekici
	13.00-13.50		
	14.00-16.50	CSL Group I (<i>Intravenous Injection & IV Cannulation</i>)	
	17.00-17.50	Independent study hours	S. Sarıkaya
23-Sep-2014 TUESDAY	09.00-09.50	Infections in Immunocompromised Host	G. Çelik
	10.00-10.50	Vaccines	G. Çelik
	11.00-11.50	Introduction to the Program of Family Medicine	G. İzbirak
	12.00-12.50	Approach to the Patient with Fever in Primary Care	Ö. Tanrıöver
	13.00-13.50		
	14.00-14.50	Planning Medical Studies	Ç. Kaspar
	15.00-15.50	Planning Medical Studies	Ç. Kaspar
	16.00-16.50	Emergency Evaluation of Sepsis and Septic Shock	S. Sarıkaya
17.00-17.50	Approach to the Pediatric Patient with Fever	Ş. Özdoğan	
24-Sep-2014 WEDNESDAY	09.00-09.50	Antihelmintic Drugs	F. Kaleağasıoğlu
	10.00-10.50	Antiseptics and Disinfectants	F. Kaleağasıoğlu
	11.00-11.50	Occupational Health Hazards I	G. Çelik
	12.00-12.50	Occupational Health Hazards II	G. Çelik
	13.00-13.50		
	14.00-16.50	CSL Group II (<i>Intravenous Injection & IV Cannulation</i>)	
	17.00-17.50	Independent study hours	S. Sarıkaya
25-Sep-2014 THURSDAY	09.00-11.50	CSL Group III (<i>Intravenous Injection & IV Cannulation</i>)	S. Sarıkaya
	12.00-12.50		
	13.00-17.50	Independent study hours	
26-Sep-2014 FRIDAY	09.00-11.50	CSL Group IV (<i>Intravenous Injection & IV Cannulation</i>)	S. Sarıkaya
	12.00-12.50		
	13.00-17.50	Independent study hours	

IV. WEEK

DAY	HOUR	SUBJECT	LECTURER
29-Sep-2014 MONDAY	09.00-09.50	Microbiology Laboratory Techniques and Diagnostic Tests Group I	İ.Ç.Acuner/ Y.G urol/G.Çelik
	10.00-10.50		
	11.00-11.50	Microbiology Laboratory Techniques and Diagnostic Tests Group II	
	12.00-12.50		
	13.00-13.50	<i>Independent study hours</i>	
	14.00-14.50	<i>Independent study hours</i>	
	15.00-15.50	<i>Independent study hours</i>	
	16.00-16.50	<i>Independent study hours</i>	
17.00-17.50	<i>Independent study hours</i>		
30-Sep-2014 TUESDAY	09.00-09.50	Microbiology Laboratory Techniques and Diagnostic Tests Group III	İ.Ç.Acuner/ Y.Gurol/G.Çelik
	10.00-10.50		
	11.00-11.50	Microbiology Laboratory Techniques and Diagnostic Tests Group IV	
	12.00-12.50		
	13.00-13.50	<i>Independent study hours</i>	
	14.00-14.50	<i>Independent study hours</i>	
	15.00-15.50	<i>Independent study hours</i>	
	16.00-16.50	<i>Independent study hours</i>	
17.00-17.50	<i>Independent study hours</i>		
01-Oct-2014 WEDNESDAY	09.00-09.50	<i>Independent study hours</i>	
	10.00-10.50	<i>Independent study hours</i>	
	11.00-11.50	<i>Independent study hours</i>	
	12.00-12.50	<i>Independent study hours</i>	
	13.00-13.50	<i>Independent study hours</i>	
	14.00-14.50	<i>Independent study hours</i>	
	15.00-15.50	<i>Independent study hours</i>	
16.00-16.50	<i>Independent study hours</i>		
17.00-17.50	<i>Independent study hours</i>		
02-Oct-2014 THURSDAY	10.00-13.00	COMMITTEE EXAM	
03-07-Oct 2014 FRIDAY- TUESDAY		Religious Holiday	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

**CARDIOVASCULAR & RESPIRATORY SYSTEMS
COMMITTEE II**

**DISTRIBUTION of LECTURE HOURS
October 8, 2014 – November 28 , 2014
COMMITTEE DURATION: 8 WEEKS**

DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• PHARMACOLOGY	PC	25				25
• PATHOLOGY	PT	24	1x3=3 (2 Groups)			27
• CHEST MEDICINE	CHM	17			1x1=1	18
• CARDIOLOGY	CRD	14				14
• PUBLIC HEALTH	PH	9				9
• BIOMEDICAL ETHICS & DEONTOLOGY	BED	9				9
• PATHOPHYSIOLOGY	PP	6				6
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	5				5
• ENT DISEASES	ENT	4				4
• THORACIC SURGERY	TS	3				3
• FAMILY MEDICINE	FM	3				3
• MEDICAL GENETICS	MG	2				2
• BIOSTATISTICS	BS	2			1x2=2	4
• PEDIATRICS	PED	2				2
• RADIOLOGY	RAD	1				1
• EMERGENCY MEDICINE	EM	1				1
• SCIENTIFIC PROJECTS-III	SP	1				1
• CLINICAL SKILLS LAB	CSL			2x3=6 (4 Groups)		6
TOTAL		128	3	6	3	140

Coordination Committee

HEAD	Sevda Özdoğan, MD, Prof.
SECRETARY	Olca Özveren, MD, Assist. Prof
MEMBER	Ferda Kaleağasıoğlu, MD Assoc. Prof.
MEMBER	Ferda Özkan, MD Prof.
MEMBER	Özlem Tanrıöver, MD, Assoc Prof (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**CARDIOVASCULAR & RESPIRATORY SYSTEMS
COMMITTEE II
LECTURERS**

DISCIPLINE	LECTURERS
CARDIOLOGY	Muzaffer Değertekin, MD Prof. Zekeriya Küçükdurmaz, MD Assoc. Prof. Olçay Özveren, MD Assist. Prof.
CHEST MEDICINE	Emine Sevda Özdoğan, MD Prof.
THORACIC SURGERY	Sina Ercan, MD Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof. Ferda Kaleağasıoğlu MD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyikan, MD, Assist. Prof.
FAMILY MEDICINE	Güldal İzbirak, MD Assoc.Prof. Özlem Tanrıöver, MD Assoc.Prof.
PEDIATRICS	Defne Çöl, MD Assist. Prof.
CLINICAL SKILLS LAB	Zekeriya Küçükdurmaz, MD Assoc. Prof Olçay Özveren, MD Assist. Prof. Ferdî Menda MD Assoc.Prof.
RADIOLOGY	Neslihan Taşdelen, MD Assoc.Prof. Ali Özgen, MD
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD Prof. Müzeyyen Doğan, MD Assoc. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Güliden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assist. Prof
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD Assoc.Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE II**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. **to convey** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. **to convey** knowledge on principles of prescription,
8. **to convey** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. **to convey** necessary knowledge on radiation physics and biology and its use in oncology,
10. **to convey** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. **to convey** knowledge on principles of biostatistical analysis,
12. **to convey** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,
13. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of cardiovascular and respiratory systems,

2. **explain** etiopathogenesis of clinical conditions (*upper respiratory tract problems -nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement - pneumonia, tuberculosis, etc.-, circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insufficiency, tobacco use, lung tumors, other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. at multi-system level and/or related to cardiovascular and respiratory systems,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices

 - which are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2)
- 6.2. evaluation of emergency case (dyspnea-C2)
- 6.3. approach to healthy individual or patient (cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2)
- 6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests-C2)
- 6.5. imaging tests/examinations (radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphy-C2, PET in lung cancer-C2)
- 6.6. point of care testing (urine strip/dipstick test-C1)
- 6.7. making preliminary diagnosis or definitive diagnosis decision
- 6.8. making non-intervention or intervention decision
- 6.9. practicing non-intervention or intervention
- 6.10. referral/transport of healthy individual or patient
7. **define** radiation physics, biology and its use in oncology,
8. **explain** principles of prescription,
9. **explain** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, bronchodilator drugs, antitussive, expectorant and surfactant drugs),
10. **explain** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),
11. **explain** principles of biostatistical analysis,
12. **explain** use of phytotherapy in an evidence based manner, and drug interactions in phytotherapy,
13. **perform** basic clinical skills, practiced on phantom models (advanced cardiac life support-C2), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition-C2), required at primary health care service.

**PHASE III
COURSE:
MD 320 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT:
COMMITTEE II
CARDIOVASCULAR & RESPIRATORY SYSTEMS**

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.,2.0.	PT	F. Özkan	9	2	1	12
1.0.,2.0.	PT	I D. Ekici	10	3	2	15
1.0.,2.0.,5.0.,6.0.	ENT	M. Doğan	1	0	0	1
1.0.,2.0.,5.0.,6.0.	ENT	Y. S. Pata	1	0	0	1
1.0.,2.0.,5.0.,6.0.	PED	D. Çöl	1	0	1	2
1.0.,2.0.,5.0.,6.0.	TS	S. Ercan	2	1	1	4
1.0.,2.0.,5.0.,6.0.6.4.	CRD	M. Değertekin	1	0	0	1
1.0.,2.0.,5.0.,6.0.6.1.,6.3.	CRD	Z. Küçükdurmaz	3	1	1	5
1.0.,2.0.,5.0.,6.0.6.4.	CRD	O. Özveren	4	1	1	6
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdoğan	12	4	1	17
2.0.,5.0.	MG	A.Ç. Kuskucu	1	0	0	1
2.0.,5.0.	PP	M. Kaçar	4	1	1	6
2.0.,5.0.,6.0.	IDCM	M. Sönmezoğlu	2	1	0	3
2.0.,5.0.,6.4.	IDCM	G. Çelik	1	0	0	1
3.0.,4.0.	PH	R.E. Sezer	4	1	0	5
3.0.,4.0.	PH	H.A. Taşyikan	3	1	1	5
6.2.	EM	S. Sarıkaya	1	0	0	1
6.3.	FM	G. İzbırak	1	0	0	1
6.3.	FM	Ö. Tanrıöver	1	0	0	1
6.5.	RAD	N. Tasdelen / A. Özgen	1	0	0	1
8.0.,9.0.	PC	F. Kaleağasıoğlu	13	4	1	18
9.0.	PC	E. Genç	5	1	1	7
10.0.	BED	E. Vatanoglu	7	2	1	10
11.0.	BS	Ç. Kaspar	3	1	1	5
TOTAL			91	24/200	14/100	129
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdoğan	2	-	-	2
1.0.,2.0.,5.0.,6.0.,6.3.,6.4.	CRD	O. Özveren	2	-	-	2
8.0.,9.0.	PC	E. Genç	1	-	-	1
TOTAL			5	-	-	5

03-07 Oct-
2014

RELIGIOUS HOLIDAY

08-10 Oct
2014

Independent study hours

II. WEEK
DAY

DAY	HOUR	SUBJECT	LECTURER
13-Oct-2014	09.00-09.50	Introduction to Committee II Pathophysiology of Cardiovascular System Disorders I	M. Kaçar
MONDAY	10.00-10.50	Pathophysiology of Cardiovascular System Disorders II	M. Kaçar
	11.00-11.50	Pathophysiology of Cardiovascular System Disorders III	M. Kaçar
	12.00-12.50	<i>Independent study hours</i>	
	13.00-13.50	<i>Independent study hours</i>	
	14.00-14.50	Epidemiology and Prevention of Cardiovascular Diseases I	H.A.Taşyikan
	15.00-15.50	Epidemiology and Prevention of Cardiovascular Diseases II	H.A.Taşyikan
	16.00-16.50	Epidemiology and Prevention of Cardiovascular Diseases III	H.A.Taşyikan
	17.00-17:50	<i>Discussion hour for the Committee I exam questions</i>	G. Çelik and Committee I Coordination Committee Members
14-Oct-2014	09.00-09.50	Examination of the Heart	M. Değertekin
TUESDAY	10.00-10.50	Approach to the patient with Cardiovascular System Diseases	Z. Küçükdurmaz
	11.00-11.50	General Signs and Principal Symptoms in Cardiovascular System Diseases	O. Özveren
	12.00-12.50	Introduction to Autonomic System Pharmacology	E. Genç
	13.00-13.50		
	14.00-14.50	Principles of Beneficence and Nonmaleficence I	E. Vatanoğlu
	15.00-15.50	Principles of Beneficence and Nonmaleficence II	E. Vatanoğlu
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17:50	<i>Independent study hours</i>	
15-Oct-2014	09.00-09.50	Electrocardiography I	Z. Küçükdurmaz
WEDNESDAY	10.00-10.50	Electrocardiography II	Z. Küçükdurmaz
	11.00-11.50	Preparing to analyse data	Ç. Kaspar
	12.00-12.50	Preparing to analyse data	Ç. Kaspar
	13.00-13.50		
	14.00-14.50	Acetylcholine and Directly Acting Parasympathomimetic Drugs	E. Genç
	15.00-15.50	Acetylcholinesterase Inhibitors	E. Genç
	16.00-16.50	<i>Independent study hours</i>	
	17.00-17:50	<i>Independent study hours</i>	

16-Oct-2014 THURSDAY	09.00-09.50	Coronary Artery Disease I	M. Değertekin
	10.00-10.50	Coronary Artery Disease II	M. Değertekin
	11.00-11.50	Cardiac Arrhythmias I	Z. Küçükdurmaz
	12.00-12.50	Cardiac Arrhythmias II	Z. Küçükdurmaz
	13.00-13.50		
	14.00-14.50	Approach to the Patient with Dyspnea in Primary Care	Ö. Tanrıöver
	15.00-15.50	End of Life decisions I	E. Vatanoglu
	16.00-16.50	Independent study hours	
17.00-17.50	Independent study hours		
17-Oct-2014 FRIDAY	09.00-09.50	Congestive Heart Failure	F. Özkan
	10.00-10.50	Congestive Heart Failure & Pericardium	F. Özkan
	11.00-11.50	Myocardium	F. Özkan
	12.00-12.50		
	13.00-13.50	Congestive Heart Failure I	O. Özveren
	14.00-14.50	Congestive Heart Failure II	O. Özveren
	15.00-15.50	Approach to the Pediatric Patient with Pneumonia	Ş. Özdoğan
	16.00-16.50	Independent study hours	
17.00-17.50	Independent study hours		

III. WEEK	HOUR	SUBJECT	LECTURER
20-Oct-2014 MONDAY	09.00-09.50	Diuretic Agents I	F. Kaleağasioğlu
	10.00-10.50	Diuretic Agents II	F. Kaleağasioğlu
	11.00-11.50	End of Life Decisions II	E. Vatanoğlu
	12.00-12.50	End of Life Decisions III	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Ischemic Heart Disease I	F. Özkan
	15.00-15.50	Ischemic Heart Disease II	F. Özkan
	16.00-16.50	Independent study hours	
	17:00-17:50	Independent study hours	
21-Oct-2014 TUESDAY	09.00-09.50	Pathology of Endocardium & Heart Valves I	I D. Ekici
	10.00-10.50	Pathology of Endocardium & Heart Valves II	I D. Ekici
	11.00-11.50	Pharmacology of Renin-Angiotensin System	F. Kaleağasioğlu
	12.00-12.50		
	13.00-13.50	Ethics of Distribution I	E. Vatanoğlu
	14.00-14.50	Ethics of Distribution II	E. Vatanoğlu
	15.00-15.50	Bloodstream Invasion & Sepsis I	G. Çelik
	16.00-16.50	Bloodstream Invasion & Sepsis II	M. Sönmezoğlu
	17:00-17:50	Independent study hours	
22-Oct-2014 WEDNESDAY	09.00-09.50	Aortic Valvular Heart Diseases	O. Özveren
	10.00-10.50	Infective Endocarditis and Acute Rheumatic fever	O. Özveren
	11.00-11.50	Anti-hypertensive Drugs-I	F. Kaleağasioğlu
	12.00-12.50	Anti-hypertensive Drugs-II	F. Kaleağasioğlu
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17:00-17:50	Independent study hours	
23-Oct-2014 THURSDAY	09.00-09.50	Cardiac Infections	M. Sönmezoğlu
	10.00-10.50	Atherosclerosis & Hypertension I	I.D. Ekici
	11.00-11.50	Atherosclerosis & Hypertension II	I.D. Ekici
	12.00-12.50	Approach to Patient with Chest Pain in Primary Care	G. İzbirak
	13.00-13.50		
	14.00-16.50	CSL Group III (Advanced Cardiac Life Support)	F. Menda
	17:00-17:50	Independent study hours	
24-Oct-2014 FRIDAY	09.00-09.50	Mitral Valvular Heart Diseases	O. Özveren
	10.00-10.50	Rheumatic Heart Disease	I D. Ekici
	11.00-11.50	CVS Tumors	I D. Ekici
	12.00-12.50	Drugs Used in Congestive Heart Disease I	F. Kaleağasioğlu
	13.00-13.50		
	14.00-14.50	Drugs Used in Congestive Heart Disease II	F. Kaleağasioğlu
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17:00-17:50	Independent study hours	

IV. WEEK

DAY	HOUR	SUBJECT	LECTURER
27-Oct-2014	10.00-10.50	Congenital Heart Disease in Pediatrics	D. Çöl
MONDAY	11.00-11.50	Congenital Heart Disease I	I. D. Ekici
	12.00-12.50	Congenital Heart Disease II	I. D. Ekici
	13.00-13.50		
	14.00-14.50	Parasympatholitic Drugs	E. Genç
	15.00-15.50	Sympathomimetic Drugs: Catecholamines & Noncatecholamines	E. Genç
	16.00-16.50	Independent study hours	
	17.00-17:50	Independent study hours	

28-29 Oct-2014

National Holiday

30-Oct-2014	09.00-09.50	History and Symptoms in Pulmonary Diseases	S. Özdoğan
THURSDAY	10.00-10.50	Physical Examination and Signs in Pulmonary Diseases	S. Özdoğan
	11.00-11.50	Adrenergic Receptor Blockers	E. Genç
	12.00-12.50	Adrenergic Neuron Blockers	E. Genç
	13.00-13.50		
	14.00-14.50	Tobacco Control and Chronic Non-Communicable Diseases I	R.E. Sezer
	15.00-15.50	Tobacco Control and Chronic Non-Communicable Diseases II	R.E. Sezer
	16.00-16.50	Independent study hours	
	17.00-17:50	Independent study hours	
31-Oct-2014	09.00-09.50	Drugs Used in Cardiac Arrhythmias I	F. Kaleağasıoğlu
FRIDAY	10.00-10.50	Drugs Used in Cardiac Arrhythmias II	F. Kaleağasıoğlu
	11.00-11.50	Drugs Used in the Treatment of Angina Pectoris	F. Kaleağasıoğlu
	12.00-12.50	Inherited Cardiovascular Disorders	A.Ç. Kuşkucu
	13.00-13.50		
	14.00-14.50	Tobacco Control and Chronic Non-Communicable Diseases III	R.E. Sezer
	15.00-15.50	Tobacco Control and Chronic Non-Communicable Diseases IV	R.E. Sezer
	16.00-16.50	Independent study hours	
	17.00-17:50	Independent study hours	

V. WEEK

DAY	HOUR	SUBJECT	LECTURER
03-Nov-2014 MONDAY	09.00-09.50	Pathophysiology of Respiratory System Disorders I	M. Kaçar
	10.00-10.50	Pathophysiology of Respiratory System Disorders I	M. Kaçar
	11.00-11.50	Pathophysiology of Respiratory System Disorders I	M. Kaçar
	12.00-12.50	Anticoagulant, Antiplatelet & Thrombolytic Drugs	F. Kaleağasıoğlu
	13.00-13.50		
	14.00-16.50	CSL Group I (Advanced Cardiac Life Support)	F. Menda
	17.00-17.50	Independent study hours	
04-Nov-2014 TUESDAY	09.00-09.50	Drugs Used in the Treatment of Dyslipidemias I	F. Kaleağasıoğlu
	10.00-10.50	Drugs Used in the Treatment of Dyslipidemias II	F. Kaleağasıoğlu
	11.00-11.50	Diagnostic Methods in Pulmonary Medicine	S. Özdoğan
	12.00-12.50	Clinical Application of Pulmonary Function Tests	S. Özdoğan
	13.00-13.50		
	14.00-16 50	CSL Group IV (Advanced Cardiac Life Support)	F. Menda
	17.00-17.50	Independent study hours	
05-Nov-2014 WEDNESDAY	09.00-09.50	Pulmonary Tuberculosis	S. Özdoğan
	10.00-10.50	Pleural Diseases	S. Özdoğan
	11.00-11.50	Pathology of Upper Respiratory Tract	F. Özkan
	12.00-12.50		
	13.00-13.50	Pulmonary Infections I	F. Özkan
	14.00-14.50	Pulmonary Infections II	F. Özkan
	15.00-17.50	Independent study hours	
06-Nov-2014 THURSDAY	09.00-09.50	Lung Diseases and Tobacco	S. Özdoğan
	10.00-10.50	Interstitial Lung Diseases	S. Özdoğan
	11.00-11.50	X-Ray Examination of the Lungs	N.Tasdelen/ A. Özgen
	12.00-12.50	Scientific Projects- III: Project Writing	G. Y. Demirel
	13.00-13.50		
	14.00-16.50	CSL Group II (Advanced Cardiac Life Support)	F. Menda
	17.00-17.50	Independent study hours	
07-Nov-2014 FRIDAY	09.00-09.50	Bronchial Hyperreactivity and Asthma	S. Özdoğan
	10.00-10.50	Chronic Obstructive Pulmonary Disease	S. Özdoğan
	11.00-11.50	Respiratory Muscles and Surgical Anatomy of Thorax	S. Ercan
	12.00-12.50	Surgical Disorders of Mediastinum and the Diaphragm	S. Ercan
	13.00-13.50		
	14.00-14.50	Surgical Treatment of Pulmonary Diseases	S. Ercan
	15.00-15.50	Pharmacology and Toxicology of Tobacco	F. Kaleağasıoğlu
	16.00-16.50	Drugs Used in the Treatment of Asthma & Chronic Obstructive Lung Disease	F. Kaleağasıoğlu
17.00-17.50	Independent study hours		

VI. WEEK DAY		SUBJECT	LECTURER
10-Nov-2014 MONDAY	09.00-09.50	Commemoration of Ataturk: Rectorate Building, Inan Kırac Conference Hall	
	10.00-10.50		
	11.00-11.50		
	12.00-17.50		
11-Nov-2014 TUESDAY	09.00-09.50	Sleep Apnea Syndrome	S. Özdoğan
	10.00-10.50	Lung Cancer	S. Özdoğan
	11.00-11.50	Tracheobronchitis	S. Özdoğan
	12.00-12.50	Treatment of Cough & Drugs Used in the Treatment of Common Cold	F. Kaleağasıoğlu
	13.00-13.50		
	14.00-16.50	CSL GROUP IV (Approach to the patient with cardiovascular disorders)	Z. Küçükdurmaz / O. Özveren
12-Nov-2014 WEDNESDAY	09.00-09.50	Pneumonia	S. Özdoğan
	10.00-10.50	Respiratory Failure	S. Özdoğan
	11.00-11.50	Principals of Statistical Analysis	Ç. Kaspar
	12.00-12.50	Principals of Statistical Analysis	Ç. Kaspar
	13.00-13.50		
	14.00-16.50	CSL GROUP I (Approach to the patient with cardiovascular disorders)	Z. Küçükdurmaz / O. Özveren
13-Nov-2014 THURSDAY	09.00-09.50	Chronic Obstructive Pulmonary Diseases	F. Özkan
	10.00-10.50	Asthma Bronchiale	F. Özkan
	11.00-11.50	Congenital Lung Anomalies & Atelectasis	F. Özkan
	12.00-12.50	Emergency Evaluation of Dyspnea	S. Sarıkaya
	13.00-13.50		
	14.00-14.50	Laryngeal and Voice Diseases	M. Doğan
	15.00-15.50	Diseases of the Middle Ear and Eustachian Tube	M. Doğan
	16.00-16.50	Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases	R.E. Sezer
	17.00-17.50	Public Health and Chronic Non-Communicable Diseases	H.A. Taşyikan
	14-Nov-2014 FRIDAY	09.00-09.50	Tumors of the Respiratory System I
10.00-10.50		Tumors of the Respiratory System II	I.D. Ekici
11.00-11.50		Pathology of Pleural and Mediastinal Diseases	I.D. Ekici
12.00-12.50		Hypertension Treatment Guidelines	F. Kaleağasıoğlu
13.00-13.50			
14.00-14.50		Approach to the Patient with Cough and Hemoptysis in Primary Care	Ö. Tanrıöver
15.00-15.50		Diseases of the Nose and Paranasal Sinuses	Y. S. Pata
16.00-16.50		Nasopharyngeal and Oropharyngeal Diseases	Y. S. Pata
17.00-17.50		Independent study hours	

VII. WEEK

DAY		SUBJECT	LECTURER
17-Nov-2014 MONDAY	09.00-09.50	Pulmoner Hypertension	S. Özdoğan
	10.00-10.50	Special Pulmonary Problems	S. Özdoğan
	11.00-11.50	End of Life Decisions I	E. Vatanoğlu
	12.00-12.50	End of Life Decisions II	E. Vatanoğlu
	13.00-13.50		
	14.00-14.50	Pathology LAB I	F. Özkan/ I.D. Ekici
	15.00-15.50	Pathology LAB I	F. Özkan/ I.D. Ekici
	16.00-16.50	Pathology LAB I	F. Özkan/ I.D. Ekici
	17.00-17.50	Independent study hours	
18-Nov-2014 TUESDAY	09.00-09.50	Pulmonary Embolism	S. Özdoğan
	10.00-10.50	Chest Medicine Case Report	S. Özdoğan
	11.00-11.50	Pharmacology Case Studies	F. Kaleağasıoğlu
	12.00-12.50	Inherited Respiratory System Disorders	A.Ç. Kuşucu
	13.00-13.50		
	14.00-14.50	Pathology LAB II	F. Özkan/ I.D. Ekici
	15.00-15.50	Pathology LAB II	F. Özkan/ I.D. Ekici
	16.00-16.50	Pathology LAB II	F. Özkan/ I.D. Ekici
	17.00-17.50	Independent study hours	
19-Nov-2014 WEDNESDAY	09.00-11.50	CSL Group III (Approach to the patient with cardiovascular disorders)	Z.Küçükdurmaz / O.Özveren
	12.00-12.50		
	13.00-17.50	Independent study hours	
20-Nov-2014 THURSDAY	09.00-12.50	Independent study hours	
	13.00-13.50		
	14.00-16.50	CSL Group II (Approach to the patient with cardiovascular disorders)	Z. Küçükdurmaz / O. Özveren
	17.00-17.50	Independent study hours	
21-Nov-2014 FRIDAY	09.00-09.50	Upper and Lower Respiratory System Infections I	G. Çelik
	10.00-10.50	Upper and Lower Respiratory System Infections II	M. Sönmezoğlu
	11.00-11.50	Chronic Restrictive Pulmonary Diseases I	I D. Ekici
	12.00-12.50	Chronic Restrictive Pulmonary Diseases II	I D. Ekici
	13.00-13.50		
	14.00-17.50	Independent study hours	

VIII. WEEK

DAY	HOUR	SUBJECT	LECTURER
24-Nov- 2014 MONDAY	09.00-17.50	<i>Independent study hours</i>	
25-Nov-2014 TUESDAY	09.00-17.50	<i>Independent study hours</i>	
26-Nov-2014 WEDNESDAY	09.00-17.50	<i>Independent study hours</i>	
27-Nov-2014 THURSDAY	09.00-17.50	<i>Independent study hours</i>	
28-Nov-2014 FRIDAY	10.00- 13.00	COMMITTEE EXAM	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

COMMITTEE III

**HEMATOPOIETIC SYSTEM
DISTRIBUTION of LECTURE HOURS**

December, 01 2014 – December, 19 2014

COMMITTEE DURATION: 3 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• HAEMATOLOGY	HEM	17				17
• PATHOLOGY	PT	10				10
• PHARMACOLOGY	PC	9				9
• PEDIATRICS	PED	7				7
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				4
• MEDICAL GENETICS	MG	3				3
• PHYTOTHERAPY	PHY	3				3
• ONCOLOGY	ONC	3				3
• PATHOPHYSIOLOGY	PP	2				2
• BIOSTATISTICS	BS	2			1X2=2	4
• BIOMEDICAL ETHICS&DEONTOLOGY	BED	2				2
• FAMILY MEDICINE	FM	1				1
• SCIENTIFIC PROJECTS- III	SP	1				1
• CLINICAL SKILLS LAB	CSL			1X3=3 (4 Groups)		3
TOTAL		64		3	2	69

Coordination Committee

HEAD	Işın D. Ekici , MD Assoc. Prof
SECRETARY	Orhan Ender Eren , MD Assist. Prof
MEMBER	Atilla Özkan, MD Assist. Prof
MEMBER	Mehtap Kaçar, MD PhD Assist. Prof. (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**HEMATOPOIETIC SYSTEM
COMMITTEE III
LECTURERS**

DISCIPLINE	LECTURERS
HAEMATOLOGY	Atilla Özkan MD Assist.Prof.
ONCOLOGY	Orhan Önder Eren, MD Assist Prof.
PATHOLOGY	Ferda Özkan, MD Prof. A.İşin Doğan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof. Ferda Kaleağasıoğlu, MD, Assoc. Prof.
PHYTOTHERAPY	Erdem YEŞİLADA, PhD, Prof.
PEDIATRICS	Ayça Vitrinel, MD Prof. Mehmet Reha Cengizlier, MD Prof. Filiz Bakar, MD Prof.
CLINICAL SKILLS LAB	Sevgi Bilgen, MD Assist Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Assoc. Prof.
BIOSTATISTICS	Çiğdem KASPAR, PhD Assist. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu, MD PhD Assist. Prof.
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof.
SCIENTIFIC PROJECTS - III	Gülderen Yanıkkaya Demirel, MD PhD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**HEMATOPOIETIC SYSTEM
COMMITTEE III**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of hematopoietic system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. **to convey** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. **to convey** knowledge on comparative biostatistical analysis of study groups,
10. **to equip with** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of hematopoietic system,
2. **explain** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
 - 6.1. practice of history taking and physical examination
 - 6.2. evaluation of emergency case
 - 6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
 - 6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
 - 6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
 - 6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
 - 6.7. making preliminary diagnosis or definitive diagnosis decision
 - 6.8. making non-intervention or intervention decision
 - 6.9. practicing non-intervention or intervention
 - 6.10. referral/transport of healthy individual or patient
7. **classify** blood products and blood groups,
8. **define** principles of transfusion,
9. **explain** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
10. **explain** mechanisms of bone marrow toxicity of drugs and other chemicals,
11. **list** principles of cancer chemotherapy,
12. **explain** chemotherapy in leukemia and lymphoma,
13. **list** phytotherapeutic agents with immunomodulatory effects,
14. **list** principles of comparative biostatistical analysis of study groups,
15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE III HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER / INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	HEM	A. Özkan	22	7	3	32
1.0.-6.0.	IM-ONC	O Ö.Eren	4	1	1	6
1.0.-6.0.	PED	A. Vitrinel	4	1	1	6
1.0.-6.0.	PED	M.R. Cengizlier	4	1	0	5
1.0.-6.0.	PED	F. Bakar	4	1	0	5
2.0.	MG	A. Ç. Kuşkucu	4	1	1	6
2.0.,5.0.	PP	M. Kaçar	2	1	0	3
2.0.,5.0.,6.4.	PT	I D. Ekici	14	4	2	20
2.0.-6.0.	IDCM	M. Sönmezoğlu	5	1	1	7
2.0.-6.4.	IDCM	G. Çelik	2	1	0	3
6.3.	FM	H. Akan	1	1	0	2
9.0.-12.0.	PC	E. Genç	2	0	0	2
9.0.-12.0.	PC	F. Kaleağasıoğlu	8	2	1	11
14.0.	BS	Ç. Kaspar	7	1	1	9
10.0	BED	E. Vatanoglu	4	1	1	6
	PHR	E. Yeşilada	3	1	1	5
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER / INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	HEM	A. Özkan	2	-	-	2
1.0.-6.0.	PED	O Ö. Eren	2	-	-	2
2.0.,5.0.,6.4.	PT	F. Kaleağasıoğlu	1	-	-	1
TOTAL			5	-	-	5

PHASE III I. WEEK DAY	COMMITTEE III HOUR	HEMATOPOIETIC SYSTEM SUBJECT	LECTURER
01-Dec-2014 MONDAY	09.00-09.50	Introduction to Committee III Introduction to Hematology, Signs and Symptoms in Hematological Diseases	M. Kaçar A. Özkan
	10.00-10.50	Classification of Anemias	A. Özkan
	11.00-11.50	Pathophysiology of Hematopoietic System Disorders I	M. Kaçar
	12.00-12.50	Pathophysiology of Hematopoietic System Disorders II	M. Kaçar
	13.00-13.50		
	14.00-14.50	Pathology of Bone Marrow-1	I D. Ekici
	15.00-15.50	Pathology of Bone Marrow-2	I D. Ekici S. Özdoğan and Committee II Coordination Committee members
	16.00-17.50	Discussion hour for the Committee II exam questions	
02-Dec-2014 TUESDAY	09.00-09.50	Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias	A.Özkan
	10.00-10.50	Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others)	A.Özkan
	11.00-11.50	Disorders of White Blood Cells& Leukemia I	I D. Ekici
	12.00-12.50	Disorders of White Blood Cells& Leukemia II	I D. Ekici
	13.00-13.50		
	14.00-16.50	CSL Group I (Femoral / Radial Arterial Puncture)	S. Bilgen
	17.00-17.50	Independent study hours	
03-Dec-2014 WEDNESDAY	09.00-09.50	Iron Metabolism and Iron Deficiency Anemia	A.Özkan
	10.00-10.50	Vitamin B ₁₂ and Folic acid Metabolism and Megaloblastic Anemias	A.Özkan
	11.00-11.50	Hodgkin's Lymphoma	I D. Ekici
	12.00-12.50	Antianemic Drugs	E. Genç
	13.00-13.50		
	14.00-14.50	Molecular Basis of Hemoglobinopathies	A. Ç. Kuşkucu
	15.00-15.50	Introduction to Clinical Oncology-I	O Ö.Eren
	16.00-16.50	Introduction to Clinical Oncology-II	O Ö.Eren
17.00-17.50	Treatment Approaches of Cancer	O Ö.Eren	
04-Dec-2014 THURSDAY	09.00-09.50	Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia	A.Özkan
	10.00-10.50	Hematopoiesis: Stem Cell and Bone Marrow	A.Özkan
	11.00-11.50	Aplastic and Hypoplastic Anemias	A.Özkan
	12.00-12.50	Pharmacological Basis of Cancer Therapy I	F. Kaleağasıoğlu
	14.00-16.50	CSL Group II (Femoral / Radial Arterial Puncture)	S.Bilgen
17.00-17.50	Independent study hours		
05-Dec-2014 FRIDAY	09.00-09.50	Chronic Leukemia	A. Özkan
	10.00-10.50	Lymphoma	A.Özkan
	11.00-11.50	Introduction to Anemias in Childhood	A. Vitrinel
	12.00-12.50	Introduction to Hemolytic Anemias	A. Vitrinel
	13.00-13.50		
	14.00-14.50	Scientific Projects- III: Project Writing	G. Yanıkkaya Demirel
	15.00-15.50	Phytotherapy-I	E. Yeşilada
	16.00-16.50	Phytotherapy-II	
17.00-17.50	Phytotherapy-III		

II. WEEK

DAY	HOUR	SUBJECT	LECTURER	
08-Dec-2014 MONDAY	09.00-09.50	Acute Leukemias	A.Özkan	
	10.00-10.50	Myeloproliferative Diseases	A.Özkan	
	11.00-11.50	Congenital Hemolytic Anemias I	M.R. Cengizlier	
	12.00-12.50	Congenital Hemolytic Anemias II	M.R. Cengizlier	
	13.00-13.50			
	14.00-16.50		CSL Group III <i>(Femoral / Radial Arterial Puncture)</i>	S.Bilgen
	17:00-17:50	Independent study hours		
09-Dec-2014 TUESDAY	09.00-09.50	Lenforeticular Infections I	G. Çelik	
	10.00-10.50	Lenforeticular Infections II	M. Sönmezoğlu	
	11.00-11.50	Lymphoreactive Disease	I D. Ekici	
	12.00-12.50	Pathology of Spleen	I D. Ekici	
	13.00-13.50			
	14.00-14.50	Genetics of Oncology I	A.Ç. Kuşkucu	
	15.00-15.50	Genetics of Oncology II	A.Ç. Kuşkucu	
	16:00-17:50	Independent study hours		
10-Dec-2014 WEDNESDAY	09.00-09.50	Pharmacological Basis of Cancer Therapy II	F. Kaleağasioğlu	
	10.00-10.50	Antineoplastic Drugs I	F. Kaleağasioğlu	
	11.00-11.50	Non/Hodgkin's Lymphoma I	I. D. Ekici	
	12.00-12.50	Non/Hodgkin's Lymphoma II	I. D. Ekici	
	13.00-13.50			
	14.00-14.50	Responsible Biomedical Research I	E. Vatanoğlu	
	15.00-15.50	Responsible Biomedical Research II	E. Vatanoğlu	
	16:00-16:50	Independent study hours		
	17:00-17:50	Independent study hours		
11-Dec-2014 THURSDAY	09.00-09.50	Comparing Groups-categorical Data	Ç. Kaspar	
	10.00-10.50	Comparing Groups-categorical Data	Ç. Kaspar	
	11.00-11.50	Antineoplastic Drugs II	F. Kaleağasioğlu	
	12.00-12.50	Non/Hodgkin's Lymphoma III	I. D. Ekici	
	13.00-13.50			
	14.00-16.50		CSL Group IV <i>(Femoral / Radial Arterial Puncture)</i>	S. Bilgen
	17:00-17:50	Independent study hours		
12-Dec-2014 FRIDAY	09.00-09.50	Hemophilia and other Coagulopathies in Childhood I	F. Bakar	
	10.00-10.50	Hemophilia and other Coagulopathies in Childhood II	F. Bakar	
	11.00-11.50	Coagulation Defects	A. Özkan	
	12.00-12.50	Quantitative and Qualitative Platelet Disorders	A. Özkan	
	13.00-13.50			
	14.00-14.50	Comparing Groups-Continuous Data	Ç. Kaspar	
	15.00-15.50	Comparing Groups-Continuous Data	Ç. Kaspar	
	16.00-16.50	Antineoplastic Drugs III	F. Kaleağasioğlu	
17.00-17.50	Immunomodulators	F. Kaleağasioğlu		

III. WEEK

DAY	HOUR	SUBJECT	LECTURER
15-Dec-2014	09.00-09.50	Blood Components and Transfusion Indications	M. Sönmezoğlu
MONDAY	10.00-10.50	Blood Groups	M. Sönmezoğlu
	11.00-11.50	Hypercoagulability	A. Özkan
	12.00-12.50	Multiple Myelom	A. Özkan
	13.00-13.50		
	14.00-14.50	Hematostatic Drugs and Hematostatic Blood Products I	E. Genç
	15.00-15.50	Hematostatic Drugs and Hematostatic Blood Products II	E. Genç
	16.00-16.50	Congenital Immunodeficiency Disease	M.R. Cengizlier
	17.00-17.50	Approach to the Patient with LAP	H. Akan
16- Dec-2014	09.00-17.50	<i>Independent study hours</i>	
TUESDAY			
17-Dec-2014	09.00-17.50	<i>Independent study hours</i>	
WEDNESDAY			
18-Dec-2014	09.00-17.50	<i>Independent study hours</i>	
THURSDAY			
19-Dec-2014	10.00-13.00	COMMITTEE EXAM	
FRIDAY			

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

COMMITTEE IV

GASTROINTESTINAL SYSTEM

DISTRIBUTION of LECTURE HOURS

December 22, 2014 - January 15, 2015

COMMITTEE DURATION: 4 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• PATHOLOGY	PT	14		1x3=3 (2 Groups)		17
• GASTROENTEROHEPATOLOGY	GE	20				20
• INTERNAL MEDICINE	IM	3				3
• BIOMEDICAL ETHICS&DEONTOLOGY	BED	4				4
• PHARMACOLOGY	PC	4				4
• PUBLIC HEALTH	PH	4				4
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				4
• BIostatISTICS	BS	2			1X2=2	4
• PHYTOTHERAPY	PHY	3				3
• CLINICAL SKILLS LAB	CSL			1X3=3 (4 Groups)		3
• PATHOPHYSIOLOGY	PP	2				2
• FAMILY MEDICINE	FM	2				2
• PEDIATRICS	PED	1				1
• PEDIATRIC SURGERY	PEDS	1				1
• RADIOLOGY	RAD	1				1
• MEDICAL GENETICS	MG	1				1
• SURGERY	GS	1				1
• EMERGENCY MEDICINE	EM	1				1
TOTAL		68		6	2	76

Coordination Committee

HEAD	Cengiz Pata, MD Prof
SECRETARY	Özlem Sönmez , MD Assist. Prof
MEMBER	Ece Genç , MD Prof
MEMBER	Ferda Özkan , MD Prof
MEMBER	Elif Vatanoğlu, MD Assist Prof (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**GASTROINTESTINAL SYSTEM COMMITTEE IV
LECTURERS**

DISCIPLINE	LECTURERS
GASTROENTEROHEPATOLOGY	Cengiz Pata, MD Prof. Ümit Akyüz, MD Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD Prof
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Assoc. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof. Ferda Kaleağasıoğlu, MD Assoc.Prof
PEDIATRICS	Meltem Uğraş, MD Assist. Prof.
PHYTOTHERAPY	Erdem Yeşilada, MD PhD Prof
PUBLIC HEALTH	Recep Erol Sezer, MD Prof Hale Arık Taşyikan, MD Assist. Prof.
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof. Özlem Tanrıöver, MD Assoc. Prof.
CSL	Orhan Önder Eren, MD Assist Prof. Özlem Sönmez, MD Assist Prof
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
RADIOLOGY	Bengi Gürses, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Meral Sömnezoğlu, MD, Assoc. Prof. Yeşim Gürol, MD, Assoc. Prof.
SURGERY	Özcan Gökçe, MD, Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

GASTROINTESTINAL SYSTEM - COMMITTEE IV

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. **to convey** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. **to convey** knowledge on biostatistical analysis of association between variables,
10. **to convey** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. **to equip with** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of gastrointestinal system,
- 2.0. **explain** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 3.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 4.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
- 5.0. **explain** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,
- 6.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 7.0. at multi-system level and/or related to gastrointestinal system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 7.1. practice of history taking and physical examination (gastrointestinal-C4)
- 7.2. evaluation of emergency case (acute abdominal pain-C4)
- 7.3. approach to healthy individual or patient (diarrhea-C4)
- 7.4. laboratory tests/examinations
- 7.5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4)
- 7.6. point of care testing
- 7.7. making preliminary diagnosis or definitive diagnosis decision
- 7.8. making non-intervention or intervention decision
- 7.9. practicing non-intervention or intervention
- 7.10. referral/transport of healthy individual or patient
8. **list** differences of gastrointestinal clinical conditions that may occur in children,
9. **explain** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),
10. **explain** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, prokinetic, laxative and purgative drugs) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
11. **explain** genetics of gastrointestinal system,
12. **explain** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
13. **define** biostatistical analysis of association between variables,
14. **tell** legal regulations and ethical principles for end-of-life decisions,
15. **perform** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE IV GASTROINTESTINAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	C. Pata	16	5	2	23
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	Ü. Akyüz	9	3	1	13
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	PEDS	S. Sözübir	1	0	0	1
1.0.,2.0.,3.0.,4.0.,6.0.,6.0.,7.1.	IM	Y. Küçükardalı	3	1	1	5
2.0.,6.0.	PP	M. Kaçar	3	1	1	5
2.0.,6.0.	PT	I. D. Ekici	5	2	1	8
2.0.,3.0.,4.0.,6.0.,7.0.	IDCM	M. Sönmezoğlu	4	1	1	6
2.0.,3.0.,4.0.,6.0.,7.3.	EM	S. Sarıkaya	1	0	0	1
2.0.,3.0.,4.0.,6.0.,7.4.	IDCM	Y. Gürol	2	1	0	3
2.0.,3.0.,4.0.,6.0.,7.4.	IDCM	G. Çelik	1	0	0	1
2.0.,6.0.,7.4.	PT	F. Özkan	16	5	1	22
3.0.,4.0.,5.0.	PH	R.E. Sezer	3	0	0	3
3.0.,4.0.,5.0.	PH	H.A. Taşyikan	2	1	1	4
5.0.	PED	M. Ugras	1	0	0	1
7.3.	FM	H. Akan	1	0	0	1
7.3.	FM	Ö. Tanrıöver	1	0	0	1
7.5.	RAD	B. Gürses	1	1	0	2
9.0.	GS	Ö. Gökçe	2	0	0	2
10.0.	PC	E. Genç	3	1	1	5
10.0.	PC	F. Kaleağasıoğlu	2	0	0	2
11.0.	MG	A.Ç. Kuskucu	2	0	0	2
13.0.	BS	Ç. Kaspar	5	1	1	7
14.0.	BED	E. Vatanoğlu	3	1	1	5
	PHR (PHY)	E. Yeşilada	3	1	1	5
TOTAL			90	25/200	13/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	C. Pata	3	-	-	3
2.0.,6.0.,7.4.	PT	F. Özkan	2	-	-	2
TOTAL			5	-	-	5

PHASE III

COMMITTEE IV

GASTROINTESTINAL SYSTEM

I. WEEK

DAY	HOUR	SUBJECT	LECTURER
22-Dec-2014	09.00-09.50	Introduction to Committee IV Semiology	E. Vatanoğlu Y. Küçükardalı
MONDAY	10.00-10.50	Semiology	Y. Küçükardalı
	11.00-11.50	Pathophysiology of Gastro-intestinal Disorders I	M. Kaçar
	12.00-12.50	Pathophysiology of Gastro-intestinal Disorders II	M. Kaçar
	13.00-13.50		
	14.00-14.50	Oral Pathology	F. Özkan
	15.00-15.50	Pathology of Esophagus I	F. Özkan
	16.00-16.50	Pathology of Esophagus II	F. Özkan
	17.00-17.50	Discussion hour for the Committee III exam questions	I.D. Ekici and Committee III Coordination Committee Members
23-Dec-2014	09.00-09.50	Acute Gastroenteritis	M. Sönmezoğlu
TUESDAY	10.00-10.50	Pathology of Stomach I	F. Özkan
	11.00-11.50	Pathology of Stomach II	F. Özkan
	12.00-12.50	Gastrointestinal Bleedings in Children	S. Sözübir
	13.00-13.50		
	14.00-14.50	Relation Between Two Variables	Ç. Kaspar
	15.00-15.50	Relation Between Two Variables	Ç. Kaspar
	16.00-16.50	Organ Transplantation and Ethics I	E. Vatanoğlu
	17.00-17.50	Organ Transplantation and Ethics II	E. Vatanoğlu
24-Dec-2014	09.00-09.50	Relation Between Several Variables	Ç. Kaspar
WEDNESDAY	10.00-10.50	Relation Between Several Variables	Ç. Kaspar
	11.00-11.50	Oral and Dental Health	
	12.00-12.50	Epidemiology, Prevention and Control of Obesity I	H.A. Taşyikan
	13.00-13.50		
	14.00-14.50	Epidemiology, Prevention and Control of Obesity II	H.A. Taşyikan
	15.00-15.50	Public Health and Nutrition I	R.E. Sezer
	16.00-16.50	Public Health and Nutrition II	R.E. Sezer
	17.00-17.50	Independent study hours	
25-Dec-2014	09.00-09.50	Jaundice	Ü. Akyüz
THURSDAY	10.00-10.50	Malabsorption	C. Pata
	11.00-11.50	Clinical Approach to the Patient with Acute Abdominal Pain	S. Sarıkaya
	12.00-12.50	Independent study hours	
	13.00-13.50		
	14.00-14.50	Pathology LAB I	F. Özkan/I.D. Ekici
	15.00-15.50	Pathology LAB I	F. Özkan/I.D. Ekici
	16.00-16.50	Pathology LAB I	F. Özkan/I.D. Ekici
	17.00-17.50	Independent study hours	
26-Dec-2014	09.00-09.50	Inflammatory Bowel Disease	C. Pata
FRIDAY	10.00-10.50	Functional GI Disorders & Irritable Bowel Disease	C. Pata
	11.00-11.50	Approach to the Patient with Diarrhea Regarding to Primary Care	H. Akan
	12.00-12.50	Food Poisoning	Y. Gürol
	13.00-13.50		
	14.00-14.50	Phytotherapy-IV	
	15.00-15.50	Phytotherapy-V	E. Yeşilada
	16.00-16.50	Phytotherapy-VI	
	17.00-17.50	Independent study hours	

II. WEEK

DAY	HOUR	SUBJECT	LECTURER
29-Dec-2014 MONDAY	09.00-09.50	Gastritis and Helicobacter Pylori	C. Pata
	10.00-10.50	Peptic Ulcer Disease	C. Pata
	11.00-11.50	Agents used in the Treatment of Peptic Ulcer I	E. Genç
	12.00-12.50	Agents used in the Treatment of Peptic Ulcer II	E. Genç
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
30-Dec-2014 TUESDAY	09.00-09.50	Gastroesophageal (GE) Reflux and Esophageal Motility Disorder	C. Pata
	10.00-10.50	Tumors of Esophagus, Stomach and Small Intestine	C. Pata
	11.00-11.50	Pathology of Intestinal Diseases I	F. Özkan
	12.00-12.50	Pathology of Intestinal Diseases II	F. Özkan
	13.00-13.50		
	14.00-14.50	Pathology Lab Group II	F. Özkan/ I.D. Ekici
	15.00-15.50	Pathology Lab Group II	F. Özkan/ I.D. Ekici
	16.00-16.50	Pathology Lab Group II	F. Özkan/ I.D. Ekici
	17.00-17.50	Independent study hours	
31-Dec -2014		Independent study day	
01-Jan-2015		NEW YEAR HOLIDAY	
02-Jan-2015 FRIDAY	09.00-09.50	Premalignant Lesion of the Colon	C. Pata
	10.00-10.50	Malignant Lesions of the Colon	C. Pata
	11.00-11.50	Hepatitis I	G. Çelik
	12.00-12.50	Hepatitis I	M. Sönmezoğlu
	13.00-13.50		
	14.00-14.50	Approach to the Patient with Abdominal Pain Regarding to Primary Care	Ö. Tanrıöver
	15.00-15.50	The Ethics of Testing and Screening I	E. Vatanoğlu
	16.00-16.50	The Ethics of Testing and Screening II	E. Vatanoğlu
	17.00-17.50	Independent study hours	

III. WEEK

DAY	HOUR	SUBJECT	LECTURER
05-Jan-2015 MONDAY	09.00-09.50	Clinical Nutrition	M. Uğraş
	10.00-10.50	Pathology of Appendix & Peritoneum	F. Özkan
	11.00-11.50	Chronic Viral Hepatitis	C. Pata
	12.00-12.50	Cirrhosis and Complications	C. Pata
	13.33-13.50		
	14.00-16.50	CSL GROUP I <i>(Approach to the patient with gastrointestinal system disorders)</i>	O.Ö. Eren
	17.00-17.50	Independent study hours	
06-Jan-2015 TUESDAY	09.00-09.50	Otoimmun Hepatitis	Ü. Akyüz
	10.00-10.50	Wilson Disease and Hemochromatosis	Ü. Akyüz
	11.00-11.50	Pathology of Liver I	F. Özkan
	12.00-12.50	Pathology of Liver II	F. Özkan
	13.00-13.50		
	14.00-16.50	CSL Group II <i>(Approach to the patient with gastrointestinal system disorders)</i>	O.Ö. Eren
	17.00-17.50	Independent study hours	
07-Jan-2015 WEDNESDAY	09.00-09.50	Drug Induced Liver Disease	C. Pata
	10.00-10.50	Mass Lesions of the Liver	C. Pata
	11.00-11.50	Prokinetic, Laxative and Purgative Drugs	F. Kaleağasıoğlu
	12.00-12.50	Emetic & Antiemetic Agents	F. Kaleağasıoğlu
	13.00-13.50		
	14.00-16.50	CSL GROUP III <i>(Approach to the patient with gastrointestinal system disorders)</i>	Ö. Sönmez
	17.00-17.50	Independent study hours	
08-Jan-2015 THURSDAY	09.00-09.50	Acute Liver Failure	Ü. Akyüz
	10.00-10.50	Disease of the Bile Duct and Gall Bladder	Ü. Akyüz
	11.00-11.50	Pathology of Liver & Biliary System I	I. D. Ekici
	12.00-12.50	Pathology of Liver & Biliary System II	I. D. Ekici
	13.00-13.50		
	14.00-16.50	CSL Group IV <i>(Approach to the patient with gastrointestinal system disorders)</i>	Ö. Sönmez
	17.00-17.50	Independent study hours	
09-Jan-2015 FRIDAY	09.00-09.50	Acute and Chronic Pancreatitis	Ü. Akyüz
	10.00-10.50	Tumors of the Bile Ducts and Pancreas	Ü. Akyüz
	11.00-11.50	Alcoholic and Nonalcoholic Liver Disease	Y. Küçükardalı
	12.00-12.50	Pathology of Liver & Biliary System III	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Pathology of Liver & Biliary System IV	I. D. Ekici
	15.00-15.50	Radiology of Gastrointestinal System	B. Gürses
	16.00-16.50	Transplantation of liver	Ö. Gökçe
	17.00-17.50	Complex diseases-Inherited Gastrointestinal System Disorders	A.Ç. Kuşkucu

IV. WEEK

12-Jan-2015 09.00-17.50 *Independent study hours*
MONDAY

13-Jan-2015 09.00-17.50 *Independent study hours*
TUESDAY

14-Jan-2015 09.00-17.50 *Independent study hours*
WEDNESDAY

15-Jan-2015 **10.00-**
13.00 **COMMITTEE EXAM**
THURSDAY

16-Jan-2015 **09:00-**
18:00 **OSCE-I EXAM**
FRIDAY

19 January – 30 January 2015 MIDTERM BREAK

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

**ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V**

**DISTRIBUTION of LECTURE HOURS
February 2, 2015 – February 27, 2015**

COMMITTEE DURATION: 4 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• PATHOLOGY	PT	20				20
• OBST & GYNEC	OBS-GYN	16				16
• ENDOCRINOLOGY	END	13				13
• INTERNAL MEDICINE	IM	2				2
• PHARMACOLOGY	PC	11				11
• MEDICAL GENETICS	MG	6				6
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	3		1x2=2 (2 Groups)		5
• PATHOPHYSIOLOGY	PP	5				5
• BIostatISTICS	BS	2			1X2=2	4
• PUBLIC HEALTH	PH	4				4
• FAMILY MEDICINE	FM	4				4
• PEDIATRICS	PED	3				3
• CLINICAL SKILLS LAB	CSL			1x3=3 (4 Groups)		3
• PHYTOTHERAPY	PHR (PHY)	2				2
• RADIOLOGY	RAD	1				1
• HISTOLOGY	HST	1				1
• SCIENTIFIC PROJECTS- III	SP	1				1
• BIOMEDICAL ETHICS&DEONTOLOGY		4				4
TOTAL		98		5	2	105

Coordination Committee

HEAD	Cem Fiçıcıoğlu, MD Prof
SECRETARY	Oluş Api, MD Assoc. Prof.
MEMBER	Hasan Aydın, MD Assoc. Prof.
MEMBER	Gülay Çiler Erdağ, MD Assist. Prof.
MEMBER	Ayşegül Ç. Kuşkucu, MD PhD Assist Prof (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V
LECTURERS**

DISCIPLINE	LECTURERS
OBSTETRICS and GYNECOLOGY	N. Cem Fıçıcıođlu, MD Prof. Oluy Api, MD Assoc. Prof. Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof.
ENDOCRINOLOGY	Hasan Aydın, MD Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Dođan Ekici, MD Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof. Ferda Kaleađasiođlu, MD Assoc. Prof.
PEDIATRICS	Gülay Çiler Erdađ, MD Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD Prof. Hale Arık Taşyikan, MD Assist. Prof.
PHYTOTHERAPY	Erdem Yeşilada, MD PhD Prof.
FAMILY MEDICINE	Özlem Tanrıöver, MD Assoc. Prof. Ayşe Arzu Akalın, MD Assist. Prof.
CLINICAL SKILLS LAB	Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof. Oluy Api, MD Assoc. Prof.
RADIOLOGY	Bengi Gürses, MD Assoc. Prof. Ali Özgen, MD
MEDICAL GENETICS	Ayşegül Çınar Kuşkuçu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gulden Çelik, MD Prof. Meral Sönmezođlu, MD Assoc. Prof. Yeşim Gürol, MD Assoc. Prof.
BIostatISTICS	Çiđdem Kaspar, PhD Assist. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanođlu, MD PhD Assist. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD Assoc. Prof.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE V

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. **to convey** knowledge on health care service practices related to reproductive care,
3. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. **to convey** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. **to convey** knowledge on genetics of endocrine and reproductive systems,
10. **to convey** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. **to convey** knowledge on design and biostatistical analysis of survival research,
12. **to convey** knowledge on legal regulations and ethical principles related to reproductive care,
13. **to equip with** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, embryology, histology and physiology of endocrine and reproductive systems,
- 2.0. **explain** physiology of normal spontaneous vaginal delivery,
- 3.0. **define** practice of reproductive care,
- 4.0. **explain** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 5.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 6.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
- 7.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 8.0. at multi-system level and/or related to endocrine and reproductive systems,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 8.1. practice of history taking and physical examination (gynecological-C5, breast-C5)
- 8.2. evaluation of emergency case
- 8.3. approach to healthy individual or patient (pregnancy-C5)
- 8.4. laboratory tests/examinations (venous blood collection-C5, throat swab specimen-C5, sputum sample collection-C5, thyroid function tests-C5, diabetes tests-C5, rapid screening [antigen/antibody] tests-C5, throat culture-C5, sputum culture-C5)
- 8.5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5, radioisotope imaging of thyroid and parathyroid-C5)
- 8.6. point of care testing (diabetes tests-C5, rapid screening [antigen/antibody] tests-C5)
- 8.7. making preliminary diagnosis or definitive diagnosis decision
- 8.8. making non-intervention or intervention decision
- 8.9. practicing non-intervention or intervention
- 8.10. referral/transport of healthy individual or patient
- 9.0. **explain** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
- 10.0. **explain** genetics of endocrine and reproductive systems,
- 11.0. **explain** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,
- 12.0. **define** design and biostatistical analysis of survival research,
- 13.0. **explain** legal regulations and ethical principles related to reproductive care,
- 14.0. **perform** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery-C5), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III						
COURSE:						
MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT:						
COMMITTEE V						
ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0	HST	O. Akçin	1	0	0	1
1.0-8.0	OBS-GYN	C. Fiçicioğlu	5	2	1	8
1.0-8.0	OBS-GYN	O. Api	5	1	1	7
1.0-8.0	OBS-GYN	R. Attar	4	1	0	5
1.0-8.0	OBS-GYN	G.Yıldırım	3	1	0	4
1.0, 4.0-8.0	END	H. Aydın	13	3	2	18
1.0, 4.0-8.0	PED	G.Ç. Erdag	4	1	0	5
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	12	1	1	14
1.0, 4.0, 7.0, 8.4	PT	I.D. Ekici	3	2	1	6
4.0, 5.0, 6.0, 7.0, 8.0	IDCM	M. Sönmezoglu	1	0	0	1
4.0, 5.0, 6.0, 7.0, 8.4	IDCM	G. Çelik	2	1	0	3
4.0, 7.0	PP	M. Kaçar	4	1	1	6
5.0, 6.0	PH	R.E. Sezer	1	1	0	2
5.0, 6.0	PH	H.A. Taşyikan	2	0	1	3
6.0, 8.0,8.1, 8.3	FM	A Akalın	3	1	0	4
8.3	FM	Ö. Tanrıöver	1	0	0	1
8.5	RAD	B. Gürses /A.Özgen	1	0	0	1
9.0	PC	E. Genç	5	2	1	8
9.0	PC	F.Kaleagasioglu	5	1	1	7
10.0	MG	A. Ç. Kuskucu	5	2	1	8
12.0	BS	Ç. Kaspar	3	1	0	4
	PHR (PHY)	E. Yesilada	2	1	0	3
10.0	BED	E. Vatanoğlu	4	2	1	7
TOTAL			89	25/200	12/100	126
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 4.0-8.0	END	H. Aydın	2	-	-	2
1.0-8.0	OBS-GYN	O.Api	2	-	-	2
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	1	-	-	1
TOTAL			5	-	-	5

PHASE III COMMITTEE V ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS

I. WEEK

DAY	HOUR	SUBJECT	LECTURER
02-Feb-2015	09.00-09.50	Introduction to Committee V Introduction to Endocrinology	A.Ç. Kuşkucu H. Aydın
MONDAY	10.00-10.50	Hyperfunctioning Disorders of Anterior Pituitary Gland	H. Aydın
	11.00-11.50	Pathology of Endocrine System: Introduction	F. Özkan
	12.00-12.50	Pathophysiology of Endocrine System Diseases I	M. Kaçar
	13.00-13.50		
	14.00-14.50	Pathophysiology of Endocrine System Diseases II	M. Kaçar
	15.00-15.50	Pathophysiology of Endocrine System Diseases III	M. Kaçar
	16.00-17.50	Discussion hour for the Committee IV exam questions	C. Pata and Committee IV Coordination Committee members
03-Feb-2015	09.00-09.50	Disorders of Posterior Pituitary Gland	H. Aydın
TUESDAY	10.00-10.50	Hypopituitarism	H. Aydın
	11.00-11.50	Thyroid Disorders	H. Aydın
	12.00-12.50	Introduction to Endocrine Pharmacology	E. Genç
	13.00-13.50		
	14.00-14.50	Design of Survival Studies	Ç. Kaspar
	15.00-15.50	Design of Survival Studies	Ç. Kaspar
	16.00-16.50	Reproductive Ethics I	E. Vatanoğlu
	17.00-17.50	Reproductive Ethics II	E. Vatanoğlu
04-Feb-2015	09.00-09.50	Hypothalamic and Pituitary Hormones I	F. Kaleağasıoğlu
WEDNESDAY	10.00-10.50	Hypothalamic and Pituitary Hormones II	F. Kaleağasıoğlu
	11.00-11.50	Thyroid Function Tests	H. Aydın
	12.00-12.50	Imaging of Thyroid Glands	B. Gürses/ A.Özgen
	13.00-13.50		
	14.00-14.50	Pathology of Thyroid & Parathyroid I	F. Özkan
	15.00-15.50	Pathology of Thyroid & Parathyroid II	F. Özkan
	16.00-16.50	Analysis of Survival Times	Ç. Kaspar
	17.00-17.50	Analysis of Survival Times	Ç. Kaspar
05-Feb-2015	09.00-09.50	Calcium Metabolism	H. Aydın
THURSDAY	10.00-10.50	Hypercalcemic Diseases	H. Aydın
	11.00-11.50	Hypocalcemic Diseases	H. Aydın
	12.00-12.50	Pathology of Adrenal Gland I	F. Özkan
	13.00-13.50		
	14.00-14.50	Pathology of Adrenal Gland II	F. Özkan
	15.00-15.50	Congenital Adrenal Hyperplasia	G.Ç. Erdağ
	16.00-16.50	Scientific Projects- III (Writing Project)	G.Y. Demirel
	17.00-17.50	Independent study hours	
06-Feb-2015	09.00-09.50	Reproductive, Maternal and Child Health I	H.A. Taşyikan
FRIDAY	10.00-10.50	Reproductive, Maternal and Child Health II	H.A. Taşyikan
	11.00-11.50	Inborn Errors of Metabolism I	A.Ç. Kuşkucu
	12.00-12.50	Inborn Errors of Metabolism II	A.Ç. Kuşkucu
	13.00-13.50		
	14.00-14.50	Reproductive Ethics III	E. Vatanoğlu
	15.00-15.50	Reproductive Ethics IV	E. Vatanoğlu
	16.00-16.50		
	17.00-17.50	Independent study hours	

II. WEEK

DAY	HOUR	SUBJECT	LECTURER
09-Feb-2015 MONDAY	09.00-09.50	Introduction to Diabetes Mellitus	Y. Küçükardalı
	10.00-10.50	Clinical and Laboratory Findings of Diabetes Mellitus	Y. Küçükardalı
	11.00-11.50	Thyroid and Antithyroid Drugs I	E. Genç
	12.00-12.50	Thyroid and Antithyroid Drugs II	E. Genç
	13.00-13.50		
	14.00-14.50	Pathology of Pituitary Gland I	I.D. Ekici
	15.00-15.50	Pathology of Pituitary Gland II	I.D. Ekici
	16.00-16.50	Phytotherapy-VII	
	17.00-17.50	Phytotherapy-VIII	E.Yeşilada
10-Feb-2015 TUESDAY	09.00-09.50	Hypoglycemia	H. Aydın
	10.00-10.50	Adrenocortical Hormones and Drugs I	E. Genç
	11.00-11.50	Adrenocortical Hormones and Dugs II	E. Genç
	12.00-12.50	Pathology of Pancreas I	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Pathology of Pancreas II	I.D. Ekici
	15.00-15.50	Reproductive, Maternal and Child Health III	H.A.Taşyikan
	16.00-16.50	Epidemiology, Prevention and Control of Type II Diabetes Mellitus	R.E. Sezer
	17.00-17.50	Independent study hours	
11-Feb-2015 WEDNESDAY	09.00-09.50	Adrenal Disorders	H. Aydın
	10.00-10.50	Obesity	H. Aydın
	11.00-11.50	Diffuse Hormonal Systems and Endocrine Tumor Syndromes	H. Aydın
	12.00-12.50	Insulin and Oral Antidiabetic Drugs I	E. Genç
	13.00-13.50		
	14.00-14.50	Insulin and Oral Antidiabetic Drugs II	E. Genç
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
12-Feb-2015 THURSDAY	09.00-09.50	Pathophysiology of Reproductive System Diseases	M. Kaçar
	10.00-10.50	Pathophysiology of Reproductive System Diseases	M. Kaçar
	11.00-11.50	Pathology of Breast I	F. Özkan
	12.00-12.50	Pathology of Breast II	F. Özkan
	13.00-13.50		
	14.00-14.50	Chromosomal Disorders I	A. Ç. Kuşkucu
	15.00-15.50	Chromosomal Disorders II (Sex chromosomes and their abnormalities)	A.Ç. Kuşkucu
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
13-Feb-2015 FRIDAY	09.00-09.50	Independent study hours	
	10.00-10.50	Pathology of Vulva & Vagina	F. Özkan
	11.00-11.50	Pathology of Cervix Uteri I	F. Özkan
	12.00-12.50	Pathology of Cervix Uteri II	F. Özkan
	13.00-13.50		
	14.00-16.50	CSL GROUP IV (Stages of normal labour)	R.Attar /G. Yıldırım/ O. Api
	17.00-17.50	Independent study hours	

III. WEEK DAY	HOUR	SUBJECT	LECTURER
16-Feb-2015 MONDAY	09.00-09.50	Antenatal Care	O. Api
	10.00-10.50	Embryology	O. Akçin
	11.00-11.50	Medical History for Breast Diseases in Primary Care BSE & Clinical Breast Examination	A. Akalın
	12.00-12.50	Genetic disorders of gonadal development	A.Ç. Kuşkucu
	13.00-13.50		
	14.00-14.50	Prenatal genetic diagnosis and genetic counseling	A.Ç. Kuşkucu
	15.00-15.50	Microbiology laboratory (Diagnostic tests of urogenital specimens) GROUP I-II Independent study hours	İ.Ç.Acuner/ Y.Gurol/G.Çelik
	16.00-16.50		
	17.00-17.50		
17-Feb-2015 TUESDAY	09.00-09.50	The Gynecological History and Examination	G.Yıldırım
	10.00-10.50	Conditions affecting Vulva & Vagina	G.Yıldırım
	11.00-11.50	Delivery of Family Planning Services I	A. Akalın
	12.00-12.50	Delivery of Family Planning Services II	A. Akalın
	13.00-13.50		
	14.00-14.50	General Approach to the Pregnant Woman	Ö. Tanrıöver
	15.00-15.50	Normal Pubertal Development	G.Ç. Erdağ
	16.00-16.50	Pubertal Disorders	G.Ç. Erdağ
	17.00-17.50	Independent study hours	
18-Feb-2015 WEDNESDAY	09.00-09.50	The Menstrual Cycle and Disorders of the Menstrual Cycle	R. Attar
	10.00-10.50	Normal and Abnormal Sexual Development & Puberty	R. Attar
	11.00-11.50	Estrogens, Progestines and Inhibitors I	F. Kaleağasıoğlu
	12.00-12.50	Estrogens, Progestines and Inhibitors II	F. Kaleağasıoğlu
	13.00-13.50		
	14.00-14.50	Normal and abnormal labor	O. Api
	15.00-15.50	Microbiology laboratory (Diagnostic tests of urogenital specimens) GROUP III-IV Independent study hours	İ.Ç.Acuner/ Y.Gurol/G.Çelik
	16.00-16.50		
	17.00-17.50		
19-Feb-2015 THURSDAY	09.00-09.50	Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD)	O. Api
	10.00-10.50	Pathology of Pregnancy & Placenta	F. Özkan
	11.00-11.50	Congenital Infections and Sexually Transmitted Diseases, Genital Infections I	G. Çelik
	12.00-12.50	Congenital Infections and Sexually Transmitted Diseases, Genital Infections II	G. Çelik
	13.00-13.50		
	14.00-14.50	Congenital Infections and Sexually Transmitted Diseases, Genital Infections	M. Sönmezoğlu
	15.00-17.50	Independent study hours	
20-Feb-2015 FRIDAY	09.00-09.50	Endometriosis & Adenomyosis	G. Yıldırım
	10.00-10.50	Puerperal Infections	O. Api
	11.00-11.50	Pathology of Treponemal Infections	F. Özkan
	12.00-12.50	Pathology of Uterus I	F. Özkan
	13.00-13.50		
	14.00-14.50	Pathology of Uterus II	F. Özkan
	15.00-17.50	CSL GROUP II (Stages of normal labour)	R.Attar /G. Yıldırım/ O. Api

IV. WEEK

DAY	HOUR	SUBJECT	LECTURER
23-Feb-2015	09.00-09.50	Benign Diseases of the Uterus and the Cervix	R. Attar
MONDAY	10.00-10.50	Benign Diseases of the Ovary	R. Attar
	11.00-11.50	Malign Diseases of the Ovary	G.Yıldırım
	12.00-12.50	Malign Diseases of the Uterus & Cervix	G.Yıldırım
	13.00-13.50		
	14.00-14.50	Pathology of Ovary I	F. Özkan
	15.00-15.50	Pathology of Ovary I	F. Özkan
	16.00-17.50	Independent study hours	
24-Feb-2015	09.00-09.50	Menopause	C. Fıçıcıoğlu
TUESDAY	10.00-10.50	Fertility Control	C. Fıçıcıoğlu
	11.00-11.50	Infertility	C. Fıçıcıoğlu
	12.00-12.50	Independent study hours	
	13.00-13.50		
	14.00-16.50	CSL GROUP I (Stages of normal labour)	R. Attar / G. Yıldırım / O. Api
	17.00-17.50	Independent study hours	
25- Feb-2015	09.00-17.50	Independent study hours	
WEDNESDAY			
26-Feb-2015	09.00-17.50	Independent study hours	
THURSDAY			
27-Feb-2015	10.00-13.00	COMMITTEE EXAM	
FRIDAY			

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

URINARY SYSTEM

COMMITTEE VI

DISTRIBUTION of LECTURE HOURS

March 02, 2015 – March 27 , 2015

COMMITTEE DURATION: 4 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• UROLOGY	URO	7				7
• NEPHROLOGY	NE	15				15
• PATHOLOGY	PT	12		1x2=2 (2 Groups)		14
• PATHOPHYSIOLOGY	PP	2				2
• PHARMACOLOGY	PC	3				3
• PEDIATRICS	PED	1				1
• PUBLIC HEALTH	PH	2				2
• CLINICAL SKILLS LAB	CSL			1x2=2 (4 Groups) 1x3=3 (4 Groups)		5
• RADIOLOGY	RAD	1				1
• MEDICAL GENETICS	MG	1				1
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2		1x2=2 (2 Groups)		4
• PEDIATRIC SURGERY	PED-S	1				1
• GENERAL SURGERY	GS	1				1
• BIostatISTICS	BS	2			1x2=2	4
• FAMILY MEDICINE	FM	1				1
TOTAL		51		9	2	62

Coordination Committee

HEAD	Gülçin Kantarcı , MD, Prof
SECRETARY	Hakan Koyuncu , MD, Assist. Prof
MEMBER	Selami Sözübir, MD, Prof.
MEMBER	Zehra Eren, MD, Assoc. Prof
MEMBER	Özlem Tanrıöver, MD Assoc Prof (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**URINARY SYSTEM
COMMITTEE VI
LECTURERS**

DISCIPLINE	LECTURERS
UROLOGY	Faruk Yencilek, MD Assoc. Prof. Ahmet Tunç Özdemir, MD Assoc. Prof. Hasbey Hakan Koyuncu, MD Assist. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD Prof. Zehra Eren, MD Assist. Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof.
PEDIATRICS	Ayça Vitrinel, MD Prof. Filiz Bakar , MD Prof.
PUBLIC HEALTH	Hale Arık Taşyikan, MD Assist. Prof.
CLINICAL SKILLS LAB	Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof. Oluş Api, MD Assoc. Prof. Güldal İzbrak, MD, Assoc. Prof. Ayşe Arzu Akalın, MD Assist. Prof. Gülay Çiler Erdağ, MD Assist. Prof. Defne Çöl, MD Assist. Prof.
RADIOLOGY	Bengi Gürses, MD Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Güliden Çelik, MD, Prof. Yeşim Gürol, MD, Assoc. Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof. Meral Sönmezoğlu, MD, Assoc. Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
GENERAL SURGERY	Özcan Gökçe, MD, Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**URINARY SYSTEM
COMMITTEE VI**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of urinary system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. **to convey** knowledge on genetics of urinary system,
9. **to convey** knowledge on phytotherapeutic agents that are effective on urinary system or on clinical conditions involving urinary system,
10. **to convey** knowledge on use of biostatistical software and presentation of results,
11. **to convey** knowledge on legal regulations and ethical principles related to reproductive care,
12. **to equip with** basic and advanced clinical skills (*gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of urinary system,
2. **explain** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
6. at multi-system level and/or related to urinary system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
 - 6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal-C6)
 - 6.2. evaluation of emergency case (urological emergencies-C6)
 - 6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6)
 - 6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture-C6, fecal culture-C6)
 - 6.5. imaging tests/examinations (uroradiology-C6, renal scintigraphy (GFR, ERPF, Renogram)-C6)
 - 6.6. point of care testing
 - 6.7. making preliminary diagnosis or definitive diagnosis decision
 - 6.8. making non-intervention or intervention decision
 - 6.9. practicing non-intervention or intervention
 - 6.10. referral/transport of healthy individual or patient
7. **explain** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. **explain** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,
9. **explain** genetics of urinary system,
10. **explain** mechanisms of action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,
11. **define** use of biostatistical software and presentation of results,
12. **perform** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6), required at primary health care service.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE VI URINARY SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	GS	Ö. Gökçe	2	0	0	2
1.0.-6.0.	NE	G. Kantarcı	14	4	2	20
1.0.-6.0.	NE	Z. Eren	7	3	1	11
1.0.-6.0.	PED	A. Vitrinel	2	1	0	3
1.0.-6.0.	PED-S	S. Sözübir	2	1	0	3
1.0.-6.0.	URO	F. Yencilek	5	1	1	7
1.0.-6.0.	URO	H. Koyuncu	3	1	1	5
1.0.-6.0.	URO	A.T.Özdemir	4	1	1	6
1.0., 2.0., 5.0., 6.4.	PT	I.D. Ekici	21	6	3	30
2.0., 5.0.	PP	M. Kaçar	2	1	0	3
2.0.-6.0.	IDCM	M. Sönmezoglu	3	1	0	3
2.0.-5.0., 6.4.	IDCM	G. Çelik	3	0	0	3
3.0., 4.0.	PH	H. A. Taşyikan	3	1	1	5
6.3.	FM	H. Akan	2	1	0	3
6.5.	RAD	B.Gürses	2	0	0	2
7.0., 8.0.	PC	E. Genç	5	1	1	7
9.0.	MG	A.Ç. Kuskucu	3	0	0	3
11.0.	BS	Ç. Kaspar	7	2	1	10
TOTAL			90	25/200	12/100	126
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	URO	A.T.Özdemir	2	-	-	2
1.0.-6.0.	NE	G. Kantarcı	2	-	-	2
1.0., 2.0., 5.0., 6.4.	PT	I.D. Ekici	1	-	-	1
TOTAL			5	-	-	5

PHASE III

COMMITTEE VI

URINARY SYSTEM

I. WEEK

DAY	HOUR	SUBJECT	LECTURER
02-Mar-2015	09.00-09.50	Introduction to Committee VI Pathophysiology of Urinary System Diseases I	M. Kaçar
MONDAY	10.00-10.50	Pathophysiology of Urinary System Diseases II	M. Kaçar
	11.00-11.50	Renovascular Pathology	I D. Ekici
	12.00-12.50	Renal Cystic Disease	I D. Ekici
	13.00-13.50		
	14.00-14.50	Independent study hours	
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
03-Mar-2015	09.00-09.50	Urolithiasis-I	F. Yencilek
TUESDAY	10.00-10.50	Urolithiasis-II	F. Yencilek
	11.00-11.50	Pathology of Male Genital System I	I. D. Ekici
	12.00-12.50	Pathology of Male Genital System II	I. D. Ekici
	13.00-13.50		
	14.00-14.50	Urinary Findings	G. Kantarcı
	15.00-15.50	Nephritic Syndrome	G. Kantarcı
	16.00-16.50	Nephrotic Syndrome	G. Kantarcı
	17.00-17.50	Discussion hour for the Committee V exam questions	C. Fıçıcıoğlu and Committee V Coordination Committee members
04-Mar-2015	09.00-09.50	Pathology of Tubulointerstitial Disease I	I. D. Ekici
WEDNESDAY	10.00-10.50	Pathology of Tubulointerstitial Disease II	I. D. Ekici
	11.00-11.50	Tubulointerstitial Diseases I	G. Kantarcı
	12.00-12.50	Tubulointerstitial Diseases I	G. Kantarcı
	13.00-13.50		
	14.00-14.50	Using Statistical Programs	Ç. Kaspar
	15.00-15.50	Using Statistical Programs	Ç. Kaspar
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
05-Mar-2015	09.00-09.50	Acute Kidney Injury I	G. Kantarcı
THURSDAY	10.00-10.50	Acute Kidney Injury II	G. Kantarcı
	11.00-11.50	Pathology of Glomerular Diseases I	I D. Ekici
	12.00-12.50	Pathology of Glomerular Diseases II	I D. Ekici
	13.00-13.50		
	14.00-16.50	CSL Group I (Gynecological examination, PAP smear obtaining / Physical examination of breast and breast self exam)	R. Attar/G. Yıldırım/O.Api/ A. Akalın/ G.İzbırak
	17.00-17.50	Independent study hours	
06-Mar-2015	09.00-09.50	Upper and Lower Urinary Tract Infections I	G. Çelik
FRIDAY	10.00-10.50	Upper and Lower Urinary Tract Infections I	M. Sönmezoğlu
	11.00-11.50	Nephritic and Nephrotic Syndrome	A. Vitrinel
	12.00-12.50	Approach to the Urinary Tract Infections	H. Akan
	13.00-13.50		
	14.00-14.50	Urologic Oncology-I	A.T. Özdemir
	15.00-15.50	Urologic Oncology-II	A.T. Özdemir
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	

II. WEEK

DAY	HOUR	SUBJECT	LECTURER
09-Mar-2015 MONDAY	09.00-09.50	Fluid, Electrolyte & Acid/Base Balance I	Z. Eren
	10.00-10.50	Fluid, Electrolyte & Acid/Base Balance II	Z. Eren
	11.00-11.50	Pathology of Glomerular Diseases III	I.D. Ekici
	12.00-12.50	Pathology of Bladder	I.D. Ekici
	13.00-13.50		
	14.00-14.50	PHYTOTHERAPY-IV	
	15.00-15.50	PHYTOTHERAPY-V	E. Yeşilada
	16.00-16.50	PHYTOTHERAPY-VI	
	17.00-17.50	Independent study hours	
10-Mar-2015 TUESDAY	09.00-09.50	Fluid, Electrolyte & Acid/Base Balance III	Z. Eren
	10.00-10.50	Fluid, Electrolyte & Acid/Base Balance IV	Z. Eren
	11.00-11.50	Congenital Anomalies of Urinary System	I.D. Ekici
	12.00-12.50	Pathology of Urinary System Tumors	I.D. Ekici
	13.00-13.50		
	14.00-16.50	CSL Group III (Gynecological examination, PAP smear obtaining / Physical examination of breast and breast self exam)	R. Attar/ G.Yıldırım/ O.Api/ A.Akalın/ G.İzbırak
	17.00-17.50	Independent study hours	
11-Mar-2015 WEDNESDAY	09.00-09.50	Benign Prostatic Hyperplasia-I	H. Koyuncu
	10.00-10.50	Benign Prostatic Hyperplasia-II	H. Koyuncu
	11.00-11.50	Congenital Anomalies of The Urinary System	S. Sözübir
	12.00-12.50	Transplantation of Kidney	Ö. Gökçe
	13.00-13.50		
	4.00-16.50	CSL Group IV (Gynecological examination, PAP smear obtaining / Physical examination of breast and breast self exam)	R. Attar/ G.Yıldırım/ O.Api/ A. Akalın/ G. İzbırak
	17.00-17.50	Independent study hours	
12-Mar-2015 THURSDAY	09.00-09.50	Microbiology laboratory (Diagnostic tests for urinary specimens) GROUP I-II	İ.Ç. Acuner/ Y. Gurol/ G. Çelik
	10.00-10.50		
	11.00-11.50	Microbiology laboratory (Diagnostic tests for urinary specimens) GROUP III-IV	İ.Ç. Acuner/ Y.Gurol/ G. Çelik
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Epidemiology, Prevention and Control of Sexually Transmitted Diseases	H.A.Taşyikan
	15.00-15.50	Epidemiology, Prevention and Control of Sexually Transmitted Diseases	H.A.Taşyikan
	16.00-17.50	Independent study hours	
13-Mar-2015 FRIDAY	09.00-17.50	Independent study hours	

III. WEEK

DAY	HOUR	SUBJECT	LECTURER
16-Mar-2015	09.00-09.50	Agents Effecting Bone Mineral Homeostasis I	E. Genç
MONDAY	10.00-10.50	Agents Effecting Bone Mineral Homeostasis II	E. Genç
	11.00-11.50	Androgens & Anabolic Steroids	E. Genç
	12.00-12.50	Imaging of Urinary System	B. Gürses
	13.00-13.50		
	14.00-16.50	CSL Group II (<i>Gynecological examination, PAP smear obtaining / Physical examination of breast and breast self exam</i>)	R. Attar/ G. Yıldırım/ O. Api/ A. Akalın/ G. İzbrak
	17.00-17.50	Independent study hours	
17-Mar-2015	09.00-09.50	Independent study hours	
TUESDAY	10.00-11.50	Pathology Group I	F. Özkan/ I.D. Ekici
	12.00-12.50		
	13.00-14.50	Pathology Group II	F. Özkan/ I.D. Ekici
	15.00-17.50	Independent study hours	
18-Mar-2015	09.00-09.50	Urologic Emergencies	F.Yencilek
WEDNESDAY	10.00-10.50	Polygenic disorders	A.Ç. Kuşku
	11.00-11.50	The Kidney Systemic Disease and Inherited Disorders I	Z. Eren
	12.00-12.50	The Kidney Systemic Disease and Inherited Disorders II	Z. Eren
	13.00-13.50		
	14.00-15.50	CSL Group IV (Physical examination of the newborn and child patient)	G.Ç. Erdağ/ D.Çöl
	16.00-17.50	CSL Group III (Physical examination of the newborn and child patient)	G.Ç. Erdağ/ D.Çöl
19-Mar-2015	09.00-09.50	The presentation of the results	Ç. Kaspar
THURSDAY	10.00-10.50	The presentation of the results	Ç. Kaspar
	11.00-11.50	Chronic Kidney Disease I	G. Kantarcı
	12.00-12.50	Chronic Kidney Disease II	G. Kantarcı
	13.00-13.50		
	14.00-15.50	CSL Group II (Physical examination of the newborn and child patient)	G.Ç. Erdağ/ D. Çöl
	16.00-17.50	CSL Group I (Physical examination of the newborn and child patient)	G.Ç. Erdağ/ D. Çöl
20-Mar-2015	09.00-17.50	Independent study hours	
FRIDAY			

IV. WEEK

DAY	HOUR	SUBJECT	LECTURER
23-Mar-2015 MONDAY	09.00-17.50	<i>Independent study hours</i>	
24-Mar-2015 TUESDAY	09.00-17.50	<i>Independent study hours</i>	
25-Mar-2015 WEDNESDAY	09.00-17.50	<i>Independent study hours</i>	
26-Mar-2015 THURSDAY	09.00-17.50	<i>Independent study hours</i>	
27-Mar-2015 FRIDAY	10:00-13:00	COMMITTEE EXAM	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

NERVOUS SYSTEM and PSYCHIATRY

COMMITTEE VII

DISTRIBUTION of LECTURE HOURS

MARCH 30, 2015 – May 08 , 2015

COMMITTEE DURATION: 6 WEEKS

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• NEUROLOGY	NR	13	1x4=4 (2 Groups)			17
• PSYCHIATRY	PCH	12				12
• CHILD PSYCHIATRY	C-PCH	3				3
• NEUROSURGERY	NRS	16	1x2=2 (2 Groups)			18
• PATHOLOGY	PT	11		1x2=2 (2 Groups)		13
• PATHOPHYSIOLOGY	PP	2				2
• PHARMACOLOGY	PC	14				14
• PEDIATRICS	PED	4				4
• PUBLIC HEALTH	PH	5				5
• FAMILY MEDICINE	FM	4				4
• CLINICAL SKILLS LAB	CSL			2x3=6 (4 Groups)		6
• RADIOLOGY	RAD	1				1
• MEDICAL GENETICS	MG	3				3
• INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2				2
• OPHTHALMOLOGY	OPT	3				3
• ANESTHESIOLOGY & REANIMATION	ANS	2				2
• BIOSTATISTICS	BS	2			1x2=2	4
• SCIENTIFIC PROJECTS- III	SP	1				1
TOTAL		98	6	8	2	114

Coordination Committee

HEAD	Başar Atalay, MD, Prof
SECRETARY	Oğuzhan Zahmacıoğlu, MD, Assist. Prof.
MEMBER	Burcu Örmeci, MD, Assist. Prof.
MEMBER	Elif Vatanoğlu, MD, Assist. Prof (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III
NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII
LECTURERS**

DISCIPLINE	LECTURERS
NEUROLOGY	Berrin Aktekin, MD, Prof. Burcu Örmeci, MD, Assist. Prof.
PSYCHIATRY	N. Berfu Akbaş, MD, Assist. Prof. Hakan Atalay, MD, Assoc. Prof.
CHILD PSYCHIATRY	Oğuzhan Zahmacıoğlu, MD, Assist. Prof.
NEUROSURGERY	M.Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Başar Atalay, MD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD, Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kalağasıoğlu, MD Assoc. Prof.
PEDIATRICS	Ayça Vitrinel, MD, Prof. Reha Cengizlier, MD, Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof.
CLINICAL SKILLS LAB	Uğur Anıl Bingöl, MD Assist. Prof. Turhan Özler MD, Assist. Prof. Hakan Koyuncu, MD Assist. Prof. N. Berfu Akbaş, MD Assist. Prof. Oğuzhan Zahmacıoğlu, MD Assist. Prof. Burcu Örmeci, MD Assist. Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc. Prof. Özlem Tanrıöver, MD, Assoc. Prof. Hülya Akan, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Assist. Prof.
RADIOLOGY	Ayşegül Sarsılmaz, MD Assist.Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD, Prof. Meral Sönmezoğlu, MD, Assoc. Prof.
OPHTALMOLOGY	Canan Aslı Yıldırım, MD, Assoc. Prof. Vildan Öztürk, MD, Assist. Prof.
ANESTHESIOLOGY & REANIMATION	Özge Köner, MD, Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD Assoc. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE VII**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of nervous system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry ,
8. **to convey** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry,
9. **to convey** necessary knowledge on common problems in medical research,
10. **to convey** knowledge on phytotherapeutic agents,
11. **to equip with** basic and advanced clinical skills (*suturing and tying-C7, neuropsychiatric evaluation-C7*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of nervous system,
- 2.0. **define** biochemical and psychodynamical basis of behavior,
- 3.0. **grade** physical, psychosocial and cognitive development of child,
- 4.0. **explain** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 5.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 6.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
- 7.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)
- 8.2. evaluation of emergency case (neurological emergencies-C7)
- 8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)
- 8.4. laboratory tests/examinations
- 8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)
- 8.6. point of care testing
- 8.7. making preliminary diagnosis or definitive diagnosis decision
- 8.8. making non-intervention or intervention decision
- 8.9. practicing non-intervention or intervention
- 8.10. referral/transport of healthy individual or patient
- 9.0. **explain** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallucinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,
- 10.0. **describe** professional standards, organizational ethics, and ethics in psychiatry,
- 11.0. **describe** phytotherapeutic agents (“HMPs, Nutraceuticals”),
- 12.0. **list** common problems in medical research,
- 13.0. **perform** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

PHASE III						
COURSE:						
MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT:						
COMMITTEE VII						
NERVOUS SYSTEM and PSYCHIATRY						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	H. Atalay	3	1	0	4
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B. Akbaş	5	1	1	7
1.0., 3.0.-8.0.	PED	R. Cengizlier	1	2	0	3
1.0., 3.0.-8.0.	PED	A. Vitrinel	3	1	0	4
1.0., 4.0., 7.0.	PT	F. Özkan	5	1	1	7
1.0., 4.0., 7.0.	PT	I.D. Ekici	5	1	1	7
1.0., 4.0.-8.0.	ANS	Ö. Köner	2	0	0	2
1.0., 4.0.-8.0.	NR	B. Aktekin	6	1	0	7
1.0., 4.0.-8.0.	NR	B. Örmeci	7	2	2	11
1.0., 4.0.-8.0.	NRS	M.G.Yaşargil	2	1	0	4
1.0., 4.0.-8.0.	NRS	B. Atalay	11	3	2	16
1.0., 4.0.-8.0.	NRS	U. Türe	2	0	1	3
1.0., 4.0.-8.0.	OPT	C.A.Yıldırım	2	0	0	2
1.0., 4.0.-8.0.	OPT	V. Öztürk	1	1	0	2
2.0.	MG	A.Ç. Kuskucu	3	0	0	3
2.0.-8.0., 10.0.	C-PCH	O. Zahmacioğlu	5	1	1	7
4.0., 7.0.	PP	M. Kaçar	2	0	0	2
4.0.-7.0, 8.4.	IDCM	G. Çelik	1	1	0	2
4.0.-8.0.	IDCM	M. Sönmezoğlu	1	1	0	2
5.0., 6.0.	PH	R.E. Sezer	2	0	0	2
8.3.	FM	H. Akan	2	1	0	3
8.3.	FM	G. Izbırak	1	1	0	2
8.3.	FM	A. Akahın	1	0	0	1
8.5.	RAD	A. Sarsılmaz	1	1	0	2
9.0.	PC	E. Genç	10	2	2	14
9.0.	PC	F. Kaleağasıoğlu	3	1	1	5
12.0.	BS	Ç. Kaspar	3	1	0	4
TOTAL			90	25/200	12/100	128
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0., 4.0.-8.0.	NR	B. Örmeci	2	-	-	2
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	H. Atalay	1	-	-	1
1.0., 4.0.-8.0.	NRS	B. Atalay	2	-	-	2
TOTAL			5	-	-	5

PHASE III COMMITTEE VII NERVOUS SYSTEM and PSYCHIATRY

I. WEEK

DAY	HOUR	SUBJECT	LECTURER
30-Mar-2015 MONDAY	09.00-09.50	Introduction to Committee VII	E. Vatanoğlu
		Signs and Symptoms in Neurology	B. Aktekin
	10.00-10.50	Cranial Nerves I	B. Aktekin
	11.00-11.50	Cranial Nerves II	B. Aktekin
	12.00-12.50		
	13.00-13.50	Pathophysiology of Nervous System Diseases I	M. Kaçar
	14.00-14.50	Pathophysiology of Nervous System Diseases II	M. Kaçar
	15.00-15.50	Public Health and Aging I	R.E. Sezer
	16.00-16.50	Public Health and Aging II	R.E. Sezer
	17.00-17.50	Independent study hours	
31-Mar-2015 TUESDAY	09.00-09.50	Cerebral Lobes and their Disorders	B. Örmeci
	10.00-10.50	Demyelinating Disorders	B. Örmeci
	11.00-11.50	Demyelinating Disorders	B. Örmeci
	12.00-12.50	Infectious Disease of the Nervous System	R. Cengizlier
	13.00-13.50		
	14.00-14.50	Infectious Diseases of CNS I	F. Özkan
	15.00-15.50	Infectious Diseases of CNS II	F. Özkan
	16.00-16.50		G. Kantarcı and Committee VI Coordination Committee Members
	17.00-17.50	Discussion hour for the Committee VI exam questions	
	01-Apr-2015 WEDNESDAY	09.00-09.50	Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient
10.00-10.50		Pediatric Neurosurgery	B. Atalay
11.00-11.50		Hydrocephalus	B. Atalay
12.00-12.50			
13.00-13.50		Power analysis and sample size calculation	Ç. Kaspar
14.00-14.50		Power analysis and sample size calculation	Ç. Kaspar
15.00-17.50		Independent study hours	
02-Apr-2015 THURSDAY	09.00-09.50	Cerebrovascular Disease	B. Örmeci
	10.00-10.50	Extrapyramidal System Disorders	B. Örmeci
	11.00-11.50	Dementia	B. Örmeci
	12.00-12.50	Acute and Chronic Meningitis, Encephalitis I	G. Çelik
	13.00-13.50		
	14.00-14.50	Acute and Chronic Meningitis, Encephalitis II	M. Sönmezoğlu
	15.00-15.50	Some Common Problems in Medical Research	Ç. Kaspar
	16.00-16.50	Some Common Problems in Medical Research	Ç. Kaspar
	17.00-17.50	Independent study hours	
03-Apr-2015 FRIDAY	09.00-09.50	Peripheral Nerve Disorders	B. Aktekin
	10.00-10.50	Epilepsy	B. Aktekin
	11.00-11.50	Introduction to Central Nervous System Pharmacology	E. Genç
	12.00-12.50	Pharmacological Approach to Parkinsonism & Other Movement Disorders	E. Genç
	13.00-13.50		
	14.00-14.50	Pathology of Myelin & Neuronal Storage Diseases I	I.D. Ekici
	15.00-15.50	Pathology of Myelin & Neuronal Storage Diseases II	I.D. Ekici
	16.00-16.50	Developmental Disorders of CNS	I.D. Ekici
	17.00-17.50	Independent study hours	

II. WEEK

DAY	HOUR	SUBJECT	LECTURER
06-Apr-2015 MONDAY	09.00-09.50	Neurodegenerative Disorders	A.Vitrinel
	10.00-10.50	Neurodegenerative Disorders I	F. Özkan
	11.00-11.50	Neurodegenerative Disorders II	F. Özkan
	12.00-12.50	Antiepileptics	E. Genç
	13.00-13.50		
	14.00-14.50	Neurosurgical Infections	B. Atalay
	15.00-15.50	Spinal Cord Compression and Spinal Tumors	B. Atalay
	16.00-16.50	Peripheral Nerve Compression Syndromes	B. Atalay
17.00-17.50	Independent study hours		
07-Apr-2015 TUESDAY	09.00-09.50	Headache in Neurologic Patient	B. Örmeci
	10.00-10.50	Neurological emergencies	B. Örmeci
	11.00-11.50	Headache in Primary Care	A. Akalın
	12.00-12.50	Cranial Trauma & Intracranial Hemorrhage I	F. Özkan
	13.00-13.50		
	14.00-14.50	Cranial Trauma & Intracranial Hemorrhage II	F. Özkan
	15.00-15.50	Scientific Projects- III: Writing Project	G. Yanıkkaya Demirel
	16.00-16.50	Sedative / Hypnotic Drugs I	E. Genç
17.00-17.50	Sedative / Hypnotic Drugs II	E. Genç	
08-Apr-2015 WEDNESDAY	09.00-09.50		
	10.00-10.50	Neurology Clinical Study & Practice Group I	B. Aktekin
	11.00-11.50		
	12.00-12.50		
	13.00-13.50	Independent study hours	
	14.00-14.50	Independent study hours	
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
17.00-17.50	Independent study hours		
09-Apr-2015 THURSDAY	09.00-09.50	Surgical Neuroanatomy	U. Türe
	10.00-10.50	Cerebrovascular Diseases in Neurosurgery I	U. Türe
	11.00-11.50	Cerebrovascular Diseases in Neurosurgery II	U. Türe
	12.00-12.50		
	13.00-13.50		
	14.00-14.50	Neurology Clinical Study & Practice Group II	B. Örmeci
	15.00-15.50		
	16.00-16.50		
17.00-17.50	Independent study hours		
10-Apr-2015 FRIDAY	09.00-09.50	Independent study hours	
	10.00-10.50	Independent study hours	
	11.00-11.50	Pathology Lab Group I	F.Özkan/ I.D.Ekici
	12.00-12.50	Pathology Lab Group I	F.Özkan/ I.D.Ekici
	13.00-13.50		
14.00-17.50	Independent study hours		

III. WEEK

DAY	HOUR	SUBJECT	LECTURER
13-Apr-2015 MONDAY	09.00-09.50	Intracranial Tumors I	M.G. Yaşargil
	10.00-10.50	Intracranial Tumors II	M.G. Yaşargil
	11.00-11.50	Degenerative Diseases of the Spine and the Spinal Cord I	B. Atalay
	12.00-12.50	Degenerative Diseases of the Spine and the Spinal Cord II	B. Atalay
	13.00-13.50		
	14.00-14.50	Tumors of CNS I	I.D. Ekici
	15.00-15.50	Tumors of CNS II	I.D. Ekici
	16.00-16.50 17.00-17.50	Independent study hours Independent study hours	
14-Apr-2015 TUESDAY	09.00-09.50	Functional Neurosurgery	B. Atalay
	10.00-10.50	Spinal Trauma in Neurosurgery	B. Atalay
	11.00-11.50	Cranial Trauma in Neurosurgery	B. Atalay
	12.00-12.50	Cerebral Malformations	A. Vitrinel
	13.00-13.50		
	14.00-14.50	Mental and Motor Development	A. Vitrinel
	15.00-15.50 16.00-16.50 17.00-17.50	Independent study hours Independent study hours Independent study hours	
	15-Apr-2015 WEDNESDAY	09.00-09.50	Neurosurgery: Clinical Practice –I
10.00-10.50			
11.00-11.50		Genetic Etiology of Mental Retardation I	A.Ç. Kuşkuçcu
12.00-12.50		Genetic Etiology of Mental Retardation II	A.Ç. Kuşkuçcu
13.00-13.50			
14.00-14.50		Conventional Neuroradiological Examinations	A. Sarsılmaz
15.00-15.50 16.00-16.50 17.00-17.50		Independent study hours Independent study hours Independent study hours	
16-Apr-2015 THURSDAY		09.00-09.50	Neurosurgery: Clinical Practice –II
	10.00-10.50		
	11.00-11.50	Opioid Analgesics & Antagonists I	E. Genç
	12.00-12.50	Opioid Analgesics & Antagonists II	E. Genç
	13.00-13.50		
	14.00-14.50	CNS Stimulants and Hallucinogenic Drugs	E. Genç
	15.00-15.50 16.00-16.50 17.00-17.50	Independent study hours Independent study hours Independent study hours	
	17-Apr-2015 FRIDAY	09.00-09.50	Introduction to Psychiatry
10.00-10.50		Signs and Symptoms in Psychiatry	H. Atalay
11.00-11.50		Introduction to General Anesthesia	Ö. Köner
12.00-12.50		Anesthetic agents	Ö. Köner
13.00-13.50			
14.00-14.50		Approach to Smoking Patient in Primary Care	H. Akan
15.00-15.50		Approach to the Patient with Dementia in Primary Care	H. Akan
16.00-16.50		Local Anesthetics	E. Genç
17.00-17.50		General Anesthetics	E. Genç

IV. WEEK

DAY	HOUR	SUBJECT	LECTURER
20-Apr-2015	09.00-09.50	Developmental Psychopathology: Risk and Protective Factors in Mental Development	H. Atalay
MONDAY	10.00-10.50	Psychopharmacology	H. Atalay
	11.00-11.50	Diseases of Optic Nerves and Visual Fields	C.A. Yıldırım
	12.00-12.50	Pupilla	C.A. Yıldırım
	13.00-13.50		
	14.00-15.50	Pathology lab Group II	F. Özkan/ I.D. Ekici
	16.00-17.50	Independent study hours	
21-Apr-2015	09.00-09.50	Schizophrenia and Psychosis I	H. Atalay
TUESDAY	10.00-10.50	Schizophrenia and Psychosis II	H. Atalay
	11.00-11.50	Antipsychotic Drugs	F. Kaleağasioğlu
	12.00-12.50	Genetic Aspects of Psychiatric Disorders	A.Ç. Kuşkucu
	13.00-13.50		
	14.00-14.50	Culture, Health and Illness	R.E. Sezer
	14.00-14.50	Epidemiology of Mental Disorders	R.E. Sezer
	14.00-14.50	Behavioral Determinants of Health and Disease	R.E. Sezer
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Independent study hours	
22-Apr-2015	09.00-09.50	Introduction to child and adolescent psychiatry	O. Zahmacioğlu
WEDNESDAY	10.00-10.50	Common Childhood Psychiatric Problems	O. Zahmacioğlu
	11.00-11.50	Mental development in childhood and adolescence	O. Zahmacioğlu
	12.00-12.50	Depression in Primary Care	G. İzbırak
	13.00-13.50		
	14.00-17.50	CSL Group I (Neuropsychiatric assessment)	N.B. Akbaş/ O. Zahmacioğlu/ B. Örmeci
23-Apr-2014		National Holiday	
THURSDAY			
24-Apr-2014	09.00-09.50	Drug Addiction & Alcoholism	B. Akbaş
FRIDAY	10.00-10.50	Organic Brain Syndromes	B. Akbaş
	11.00-11.50	Mood Disorders	B. Akbaş
	12.00-12.50	Paralytic Strabismus and Nistagmus	V. Öztürk
	13.00-13.50		
	14.00-17.50	CSL Group IV (Suturing materials and suturing technique)	U.A. Bingöl

V. WEEK

DAY	HOUR	SUBJECT	LECTURER
27-Apr-2014 MONDAY	09.00-09.50	Anxiety Disorders I	B. Akbaş
	10.00-10.50	Anxiety Disorders I	B. Akbaş
	11.00-11.50	Psychotherapies	B. Akbaş
	12.00-12.50	Bipolar Disease & Lithium	F. Kaleağasıoğlu
	13.00-13.50		
	14.00-14.50	Drug Dependence & Abuse	E. Genç
	15.00-15.50	Antidepressant Drugs	E. Genç
	16.00-16.50	The Alcohols	E. Genç
17.00-17.50	Independent study hours		
28-Apr-2014 TUESDAY	09.00-12.50	CSL Group III (Neuropsychiatric assessment)	N.B.Akbaş/ O.Zahmacıoğlu/ B.Örmeci
	13.00-13.50		
	14.00-17.50	CSL Group II (Suturing materials and suturing technique)	T. Özler
29-Apr-2014 WEDNESDAY	09.00-12.50	CSL Group II (Neuropsychiatric assessment)	N.B.Akbaş/ O.Zahmacıoğlu/ B.Örmeci
	13.00-13.50		
	14.00-17.50	CSL Group I (Suturing materials and suturing technique)	H. Koyuncu
30-Apr-2015 FRIDAY	09.00-12.50	CSL Group IV (Neuropsychiatric assessment)	N.B.Akbaş/ O. Zahmacıoğlu/ B. Örmeci
	13.00-13.50		
	14.00-17.50	CSL Group III (Suturing materials and suturing technique)	H. Koyuncu
01-May-2015 FRIDAY	LABOR'S DAY		

VI. WEEK DAY	HOUR	SUBJECT	LECTURER
04-May-2015 MONDAY	09.00-17.50	Independent study hours	<i>SPRING FEST</i>
05-May-2015 TUESDAY	09.00-17.50	Independent study hours	<i>SPRING FEST</i>
06-May-2015 WEDNESDAY	09.00-17.50	Independent study hours	<i>SPRING FEST</i>
07-May-2015 THURSDAY	09.00-17.50	Independent study hours	<i>SPRING FEST</i>
08-May-2015 FRIDAY	10.00-13.00	COMMITTEE EXAM	

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE**

PHASE III

**MUSCULOSKELETAL SYSTEM
COMMITTEE VIII
DISTRIBUTION of LECTURE HOURS
MAY 11, 2015 – JUNE 05, 2015
COMMITTEE DURATION: 4 WEEKS**

• DISCIPLINE	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
• ORTHOPAEDICS & TRAUMATOLOGY	ORT	20				20
• PHYSICAL THERAPY & REHABILITATION	PTR	4				4
• RHEUMATOLOGY	RHE	8				8
• PATHOLOGY	PT	11		1x2=2 (4 Groups)		13
• PATHOPHYSIOLOGY	PP	2				2
• PHARMACOLOGY	PC	7				7
• PUBLIC HEALTH	PH	5				5
• FAMILY MEDICINE	FM	2				2
• CLINICAL SKILLS LAB	CSL			1x3=3 (4 Groups)		3
• MEDICAL GENETICS	MG	2				2
• RADIOLOGY	RAD	1				1
• BIOMEDICAL ETHICS & DEONTOLOGY	BED	2				2
• EMERGENCY MEDICINE	EM	1				1
• BIOSTATISTICS	BS	2			1x2	4
TOTAL		67	0	5	2	74

Coordination Committee

HEAD	Melih Güven, MD Assoc. Prof
SECRETARY	Müge Bıçakçığıl, MD Assoc. Prof
MEMBER	Ece Aydoğ, MD Prof
MEMBER	Çağatay Uluçay, MD Assist. Prof
MEMBER	Mehtap Kaçar, MD PhD Assist. Prof. (Co-coordinator)

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**MUSCULOSKELETAL SYSTEM
COMMITTEE VIII**

LECTURERS

DISCIPLINE	FACULTY
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD, Prof. Melih Güven, MD, Assoc.Prof. Turhan Özler, MD, Assist. Prof. Çağatay Uluçay, MD, Assist. Prof.
PHYSICAL THERAPY & REHABILITATION	Ece Aydoğ, MD, Prof.
RHEUMATOLOGY	Müge Bıçakçığıl, MD, Assoc. Prof
PATHOLOGY	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD, Assist. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof Hale Arık Taşyikan, MD, Assist. Prof
FAMILY MEDICINE	Özlem Tanrıöver, MD, Assoc. Prof Hülya Akan, MD, Assoc. Prof.
CLINICAL SKILLS LAB	Turhan Özler, MD, Assist. Prof. Çağatay Uluçay, MD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, PhD Assist. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD PhD, Assist Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc.Prof
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

**MUSCULOSKELETAL SYSTEM
COMMITTEE VIII**

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. **to convey** necessary knowledge on ethics in biomedical research,
9. **to convey** necessary knowledge on clinical research methods and searching medical literature,
10. **to convey** necessary knowledge on phytotherapeutic agents,
11. **to equip with** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

- 1.0. **recall** anatomy, histology and physiology of musculoskeletal system,
- 2.0. **explain** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, oncological conditions of bone, rheumatological disorders, diseases/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 3.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 4.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
- 5.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
 - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
 - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
 - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
 - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (musculoskeletal-C8)
- 6.2. evaluation of emergency case (trauma-C8)
- 6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
- 6.4. laboratory tests/examinations (monitorization of drug therapy-C8)
- 6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
- 6.6. point of care testing
- 6.7. making preliminary diagnosis or definitive diagnosis decision
- 6.8. making non-intervention or intervention decision
- 6.9. practicing non-intervention or intervention
- 6.10. referral/transport of healthy individual or patient
- 7.0. **explain** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
- 8.0. **explain** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,
- 9.0. **list** ethical principles in biomedical research,
- 10.0. **explain** use of biostatistics in clinical research and for evidence search in medical literature,
- 11.0. **perform** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

**YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III**

PHASE III COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE VIII MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	ORT	F. Altıntas	6	2	1	9
1.0.-6.0.	ORT	T. Özler	7	1	1	9
1.0.-6.0.	ORT	Ç. Uluçay	5	3	2	10
1.0.-6.0.	ORT	M. Güven	11	2	1	14
1.0.-6.0.	PTR	E. Aydoğ	4	1	1	6
1.0.-6.0.	RHE	M. Bıçakçığıl	8	2	1	11
1.0., 2.0., 5.0.	PP	M. Kaçar	2	1	0	3
1.0., 2.0., 5.0.	PT	F. Özkan	10	2	1	13
1.0., 2.0., 5.0.	PT	I.D. Ekici	6	1	1	8
2.0.	MG	A.Ç. Kuşkuçu	2	1	0	3
3.0., 4.0.	PH	R.E. Sezer	4	1	1	6
3.0., 4.0.	PH	H.A. Taşyikan	3	1	0	4
6.2.	EM	S. Sarıkaya	1	0	0	1
6.3.	FM	H. Akan	1	1	0	2
6.3.	FM	Ö. Tanrıöver	1	1	0	2
6.5.	RAD	N. Taşdelen	1	1	0	2
7.0.	PC	F. Kaleağasıoğlu	6	1	1	8
7.0.	PC	E. Genç	3	1	0	4
9.0.	BED	E. Vatanoğlu	3	1	0	4
10.0.	BS	Ç. Kaspar	6	1	1	8
TOTAL			90	25/200	12/100	127
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	RHE	M. Bıçakçığıl	2	-	-	2
1.0.-6.0.	ORT	M. Güven	2	-	-	2
1.0.-6.0.	PTR	E. Aydoğ	1	-	-	1
TOTAL			5	-	-	5

PHASE III COMMITTEE VIII MUSCULOSKELETAL SYSTEM

I. WEEK DAY	HOUR	SUBJECT	LECTURER
11-May-2015 MONDAY	09.00-09.50	Introduction to Committee VIII	M. Kaçar
		Introduction to Musculoskeletal System	F. Altıntaş
	10.00-10.50	Public Health and Physical Activity I	R.E. Sezer
	11.00-11.50	Public Health and Physical Activity II	R.E. Sezer
	12.00-12.50		
	13.00-13.50	Pathophysiology of Musculoskeletal System Disorders I	M. Kaçar
	14.00-14.50	Pathophysiology of Musculoskeletal System Disorders II	M. Kaçar
	15.00-15.50	Independent study hours	
	16.00-16.50	Independent study hours	
	17.00-17.50	Discussion hour for the Committee VII exam questions	B. Atalay and Committee VII Coordination Committee Members
12-May-2015 TUESDAY	09.00-09.50	Lower Extremity Disorders	Ç. Uluçay
	10.00-10.50	Foot Deformities	Ç. Uluçay
	11.00-11.50	Epidemiology, Prevention and Control of Occupational Diseases and Injuries I	H.A. Taşyikan
	12.00-12.50	Epidemiology, Prevention and Control of Occupational Diseases and Injuries II	H.A. Taşyikan
	13.00-17.50	Independent study hours	
13-May-2015 WEDNESDAY	09.00-09.50	Developmental Disorders of the Skeleton	M. Güven
	10.00-10.50	Congenital Dislocation of the Hip	M. Güven
	11.00-11.50	Congenital & Metabolic Diseases of Bone I	F. Özkan
	12.00-12.50	Congenital & Metabolic Diseases of Bone II	F. Özkan
	13.00-13.50		
	14.00-14.50	Introduction to Occupational Health	R.E. Sezer
	15.00-15.50	Ethics of Testing and Screening	E. Vatanoğlu
	16.00-16.50	Ethics of Testing and Screening	E. Vatanoğlu
17.00-17.50	Independent study hours		
14-May-2015 THURSDAY	09.00-09.50	Osteomyelitis and Septic Arthritis	M. Güven
	10.00-10.50	Upper Extremity Disorders	Ç. Uluçay
	11.00-11.50	Inflammatory Polyarthritis & Rheumatoid Arthritis	M. Bıçakçıl
	12.00-12.50	Bone and Joint Infections	I.D. Ekici
	13.00-13.50		
	14.00-14.50	Nonsteroidal Antiinflammatory Drugs I	E. Genç
	15.00-15.50	Nonsteroidal Antiinflammatory Drugs II	E. Genç
	16.00-16.50	Independent study hours	
17.00-17.50	Independent study hours		
15-May-2015 FRIDAY	09.00-09.50	Osteoporosis	Ç. Uluçay
	10.00-10.50	Degenerative Osteoarthritis	F. Altıntaş
	11.00-11.50	Degenerative Joint Disease	F. Özkan
	12.00-17.50	Independent study hours	

II. WEEK

DAY	HOURL	SUBJECT	LECTURER
18-19-May-2015 MONDAY- TUESDAY		National Holiday	
20-May-2015 WEDNESDAY	09.00-09.50 10.00-10.50 11.00-11.50 12.00-12.50 13.00-13.50 14.00-14.50 15.00-15.50 16.00-16.50 17:00-17:50	Neuromuscular Disease Spondylarthropaties Connective Tissue Disorders I Connective Tissue Disorders II Soft Tissue Pain Osteoporosis and Osteoarthritis Treatment, Rehabilitation Independent study hours Independent study hours	M. Güven M. Bıçakçığıl M. Bıçakçığıl M. Bıçakçığıl E. Aydoğ E. Aydoğ
21-May-2015 THURSDAY	09.00-09.50 13.00-10.50 11.00-11.50 12.00-12.50 13.00-13.50 14.00-14.50 15.00-15.50 16.00-16.50 17:00-17:50	Low Back, Hip and Ankle Pain Neck, Shoulder and Wrist Pain Sport Injuries I Sport Injuries II Medical Literature Medical Literature Vasculitis I Vasculitis II	E. Aydoğ E. Aydoğ T. Özler T. Özler Ç. Kaspar Ç. Kaspar M. Bıçakçığıl M. Bıçakçığıl
22-May-2015 FRIDAY	09.00-09.50 10.00-10.50 11.00-11.50 12.00-12.50 13.00-13.50 14.00-14.50 15.00-15.50 16.00-16.50 17:00-17:50	Miscellaneous Rheumatological Disorders I Miscellaneous Rheumatological Disorders II Microsurgery and Replantation Trauma Skeletal Muscle Relaxants Disease Modifying Antirheumatic Drugs Pharmacology Case Studies Independent study hours	M. Bıçakçığıl M. Bıçakçığıl T. Özler T. Özler E. Genç F. Kaleağasiođlu E. Genç / F. Kaleağasiođlu

III. WEEK

DAY	HOUR	SUBJECT	LECTURER
25-May-2015 MONDAY	09.00-09.50	Traumatic Dislocations	Ç. Uluçay
	10.00-10.50	Spinal Deformities	Ç. Uluçay
	11.00-11.50	Benign Tumors of Bone	M. Güven
	12.00-12.50	Malignant Tumors of Bone	M. Güven
	13.00-13.50		
	14.00-14.50	Principles of Fracture Healing	F. Altıntaş
	15.00-15.50	Myopathies	I.D. Ekici
	16.00-16.50	Independent study hours	
17.00-17.50	Independent study hours		
26-May-2015 TUESDAY	09.00-09.50	Fractures of Children	M. Güven
	10.00-10.50	Vasculitis/I	F. Özkan
	11.00-11.50	Vasculitis/I	F. Özkan
	12.00-12.50	Approach to the Patient with Backpain in Primary Care	Ö. Tanrıöver
	13.00-13.50	Fibromyalgia in Primary Care	H. Akan
	14.00-14.50		
	15.00-15.50	Imaging of Musculoskeletal System	N. Taşdelen
	16.00-16.50	Independent study hours	
17.00-17.50	Independent study hours		
27-May-2015 WEDNESDAY	09.00-09.50	Independent study hours	
	10.00-10.50	Independent study hours	
	11.00-11.50	Independent study hours	
	12.00-12.50	Independent study hours	
	13.00-13.50		
	14.00-16.50	CSL Group II (Physical examination of the musculoskeletal system)	T. Özler/ Ç.Uluçay
	17.00-17.50	Independent study hours	
28-May-2015 THURSDAY	09.00-09.50	Tumors of Soft Tissues I	F. Özkan
	13.00-10.50	Tumors of Soft Tissues II	F. Özkan
	11.00-11.50	Skeletal Dysplasias	A.Ç. Kuşku
	12.00-12.50	Muscular Dystrophies	A.Ç. Kuşku
	13.00-13.50		
	14.00-14.50	Initial Approach to Trauma Patient	S. Sarıkaya
	15.00-17.50	CSL Group IV (Physical examination of the musculoskeletal system)	T. Özler/ Ç.Uluçay
29-May-2015 FRIDAY	09.00-09.50	Upper Extremity Trauma	T. Özler
	10.00-10.50	Lower Extremity Trauma	T. Özler
	11.00-11.50	Clinical Trials	Ç. Kaspar
	12.00-12.50	Clinical Trials	Ç. Kaspar
	13.00-13.50		
	14.00-16.50	CSL Group I (Physical examination of the musculoskeletal system)	T. Özler/ Ç.Uluçay
	17.00-17.50	Independent study hours	

IV. WEEK

DAY	HOUR	SUBJECT	LECTURER
01-June-2015 MONDAY	09.00-09.50	Bone tumors I	I.D. Ekici
	10.00-10.50	Bone tumors II	I.D. Ekici
	11.00-11.50	Pathology Lab Groups: I-II	I.D. Ekici
	12.00-12.50		
	13.00-13.50	CSL Group III <i>(Physical examination of the musculoskeletal system)</i>	T. Özler/ Ç.Uluçay
	14.00-16.50		
17.00-17.50	<i>Independent study hours</i>		
02-June-2015 TUESDAY	09.00-17.50	<i>Independent study hours</i>	
03-June-2015 WEDNESDAY	09.00-17.50	<i>Independent study hours</i>	
04-June-2015 THURSDAY	09.00-17.50	<i>Independent study hours</i>	
05-June-2015	10.00-13.00	COMMITTEE EXAM	
FRIDAY	14.00-15.00	<i>Discussion hour for the Committee VIII exam questions</i>	M. Güven and Committee VIII Coordination Committee members
08-June-2015 MONDAY	09:00-18:00	OSCE-II EXAM	
29-June-2015 MONDAY		FINAL EXAM	
24-July-2015 FRIDAY		INCOMPLETE EXAM	

Contact

Faculty Secretary:

Tel: +90 216 578 05 93

Dean Secretary:

Tel: +90 216 578 05 05-06

Fax: +90 216 578 05 75

Student Affairs:

Tel: 0216 578 06 86

Document Affairs:

Tel: 0216 578 05 23

PHASE III COORDINATION COMMITTEE

Gülderen Yanıkkaya Demirel MD, Assoc. Prof. (Coordinator) 0216 578 00 00 (3218)/

gulderen.ydemirel@yeditepe.edu.tr

Özlem Tanrıöver, Assoc. Prof. (Co-coordinator) 0216 578 00 00 (3742) / otanriover@yeditepe.edu.tr

Ayşegül Kuşkucu, MD, PhD Assist. Prof. (Co-coordinator) 0216 578 00 00 (5777)/

aysegul.kuskucu@yeditepe.edu.tr

Elif Vatanoglu, MD, Assist. Prof. (Co-coordinator) 0216 578 00 00(3078)/ elif.vatanoglu@yeditepe.edu.tr

Mehtap Kaçar, MD, Assist. Prof. (Co-coordinator) 0216 578 00 00 (1419)/ mehtap.kacar@yeditepe.edu.tr

ICP III COORDINATION COMMITTEE

Özlem Tanrıöver MD, Assoc. Prof. (ICP Coordinator) 216 578 00 00 (3742)/ otanriover@yeditepe.edu.tr

A. Arzu Akalın MD, Assist. Prof. (ICP Co-coordinator) 216 578 00 00 (1525)/ arzu.akalin@yeditepe.edu.tr

Turhan Özler MD, Assist. Prof. (ICP Co-coordinator) 0216 578 00 00 (4051)/ turhan.ozler@yeditepe.edu.tr

Address:

Yeditepe University Faculty of Medicine

İnönü Mah., Kayışdağı Caddesi,

26 Ağustos Yerleşimi,

34755 Ataşehir, İstanbul

Web: www.yeditepe.edu.tr

<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>

e-mail: tipfakdek@yeditepe.edu.tr



YEDİTEPE UNIVERSITY
FACULTY of MEDICINE

İnönü Mahallesi, Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

Tel: (+90 216) 578 00 00

www.yeditepe.edu.tr
<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>
tipfakdek@yeditepe.edu.tr